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ABSTRACT: This article posits that collaborative 
models of technology transfer could be considered 
for their remarkable ability to maintain or 
increase the pace and quality of scientific 
development in stem cell research rather than for 
their potential to fix problems that do not 
empirically exist. In light of this scientific field’s 
logistical constraints and its current stage of 
development, the open model appears to be a 
particularly suitable collaborative method of 
technology management for stem cell research. 
KEYWORDS: stem cell; technology transfer; 
open model.
RESUMO: Este artigo postula que os modelos 
colaborativos de transferência de tecnologia 
poderiam ser considerados por sua notável 
habilidade em manter ou aumentar o ritmo e a 
qualidade do desenvolvimento científico na 
pesquisa em célula tronco, ao invés de serem 
considerados por seu potencial em colocar 
problemas que empiricamente não existem. À luz 
destas limitações logísticas do campo científico e 
do seu presente estágio de desenvolvimento, o 
modelo aberto parece ser um método colaborativo 
particularmente adequável de gestão de tecnologia 
para a pesquisa em célula tronco. 
PALAVRAS-CHAVE: células tronco; transferência 
de tecnologia; modelo aberto.
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INTRODUCTION
Stem cell research is perceived by both 
academia and the media as a turning point in 
modern medicine. Indeed, the results of the 
research in this area are likely to have 
profound implications for our society. 
However, the successful transition of this 
important research from being of merely 
scientific interest to having concrete clinical 
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utility will depend in large part on whether 
our current technology transfer methods are 
sufficiently responsive to the characteristics 
of this novel discipline. Of particular concern 
is that the use of both patents and restrictive 
material transfer agreements could unduly 
interfere with the transfer of foundational 
stem cells technologies and cause them to be 
lost down the proverbial rabbit hole. Although 
supported by little empirical data thus far, this 
intuitive feeling is very present within the 
scientific community and has led many to 
criticize the current technology transfer 
process and its unsuitability for this new and 
potentially groundbreaking field. It is thus 
necessary that we consider the alternatives.
The therapeutic potential of stem cell 
research along with the vast sums of money 
invested in this area justify that we pay special 
attention to the transfer of stem cell research 
such that these innovations may be translated 
into clinically beneficial treatments as quickly 
and efficiently as possible. With this objective 
in mind, the following article explores the need 
for, and the benefits of, open science models, 
i.e. non-proprietary management modes, as 
suitable alternatives for the transfer of 
technology in human stem cell research. To 
do so, the authors will begin with a brief 
overview of the promise of stem cell research 
and continue with an explanation of its 
relationship to systems of intellectual property 
protection. Then, the article will discuss the 
various attributes of open science models and 
assess their potential in the field of stem cell 
research. Our findings will be supported by 
the case studies. It will be seen that open 
models of technology transfer, although not 
appropriate substitutes for intellectual property 
rights in all circumstances, could provide 
interesting alternatives for, or complements to, 
standard property schemes at various stages 
in the technology transfer process.
1. THE SCIENTIFIC POTENTIAL OF 
STEM CELLS
A) The Scientific Potential of Stem Cells
Stem cells are cells that possess two 
identifiable properties: they are undifferentiated 
and renewable. An undifferentiated cell refers 
to a cell that can transform into a specialized 
cell type and a renewable cell is a cell that 
possesses the ability to multiply through cell 
division.1 It is also precisely because of these 
two properties that stem cell research is being 
touted as an exciting new field of development 
that could shed new light on all aspects of 
medicine: 2
Stem cells have the remarkable potential to 
develop into many different cell types in the 
body. Serving as a sort of repair system for the 
body, they can theoretically divide without 
limit to replenish other cells as long as the 
person or animal is still alive. When a stem 
cell divides, each new cell has the potential to 
either remain a stem cell or become another 
type of cell with a more specialized function, 
such as a muscle cell, a red blood cell, or a 
brain cell.3
1 Douglas C. Wu, Ashleigh S. Boyd & Kathryn J. 
Wood, Embryonic Stem Cell Transplantation: Potential 
Applicability in Cell Replacement Therapy Regenerative 
Medicine, 12 Frontiers in Bioscience, 4525-4535 (2007). 
2 The Steering Committee of the International Stem 
Cell Initiative, The International Stem Cell Initiative: 
Toward Benchmarks for Human Embryonic Stem Cell 
Research, 23(7) Nature Biotechnology, 796 (2005).
3 National Institutes for Health, Stem Cell Basics, 
http://stemcells.nih.gov/info/basics/ (last visited 
November 30, 2007). 
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Stem cells are categorized according to 
the types of cells that they can engender.4 
Totipotent stem cells can differentiate into 
any type of cell and can therefore transform 
into any cell needed for the development of 
a living being. Totipotent stem cells are 
produced either by the fusion of a sperm cell 
and an egg cell or by the first few divisions 
of the fertilized egg. Pluripotent stem cells 
also retain the ability to differentiate into a 
number of specialized cells. What pluripotent 
stem cells cannot transform into however, 
are the cells necessary to the development 
of the placenta which is essential for 
gestation to occur. This type of stem cell is 
produced between the fifth and seventh days 
after the fertilization of the egg. Multipotent 
stem cells, although capable of further 
differentiation, are only capable transforming 
into specific types of tissues. For example, 
haematopoietic stem cells found in bone 
marrow and the umbilical cord can only 
engender white blood cells, red blood cells, 
and platelets.5 Finally and in complete 
opposition to totipotent stem cells, unipotent 
4 Comité consultatif national d’éthique pour les 
sciences de la vie et de la santé, Avis no. 93 Commercialisation 
des cellules souches humaines et autres lignées cellulaires 
7 (Comité consultatif national d’éthique pour les sciences 
de la vie et de la santé 2006) (2006); Bernard Edward Tuch, 
Stem Cells : A Clinical Update, 35(9) Australian Family 
Physician, 719-721 (2006). 
5 Alison Murdoch, Human Embryonic Stem Cells: 
An Introduction, 5 Human Fertility, 203-205 (2002); 
National Institutes for Health, Highlights of Stem Cell 
Research, http://stemcells.nih.gov/research/scilit/
highlights/DefaultPage.html (last visited November 30, 
2007). It should also be noted that recent developments 
have touted amniotic fluid-derived stem cells as being 
multipotent stem cells. However, these findings have yet 
to be widely confirmed by the scientific community.
stem cells can produce only one type 
of cell.6 
For research purposes, stem cells must be 
removed or isolated from their tissue source.7 
To date, there are two methods that allow for 
the isolation of stem cells. First, multipotent 
and unipotent stem cells can be retrieved 
directly from born alive individuals. Indeed, 
whereas multipotent stem cells can be found, 
among others, in bone marrow, in the 
umbilical cord, and in the amniotic fluid, 
unipotent stem cells can be found in the 
epidermis. However, due to the relatively 
limited capacity of both these types of stem 
cells to differentiate, they are not as sought 
after as embryonic totipotent and pluripotent 
stem cells.8 This leads us to a discussion of 
the other method of isolation that is concerned 
with embryonic stem cells. 
Human embryonic stem cells (hESC) are 
isolated by the extraction of stem cells from 
an embryo. The embryos in question are often 
supernumerary embryos resulting from in 
vitro fertilization (IVF) procedures.9 However, 
6 Comité consultatif national d’éthique pour les 
sciences de la vie et de la santé, supra note 4, at 8. For 
instance, this is the case of keratinocyte cells that make 
up the skin. In other words, keratinocyte stem cells can 
only create other keratinocyte cells. 
7 National Institutes for Health, FAQs, http://stemcells.
nih.gov/StemCells/Templates/StemCellContentPage.aspx?NR
MODE=Published&NRNODEGUID=%7bA604DCCE-
2E5F-4395-8954-FCE1C05BECED%7d&NRORIGINALU
RL=%2finfo%2ffaqs%2easp&NRCACHEHINT=NoModify
Guest#excited (last visited November 30, 2007). 
8 The President’s Council on Bioethics, Monitoring 
Stem Cell Research 7-11, (The President’s Council on 
Bioethics 2004) (2004). 
9 Russell Korobkin & Stephen Munzer, Stem Cell 
Research and Law 7-8, (UCLA Center for Society and 
Genetics, UCLA School of Law 2006) (2006); Alison 
Murdoch, Human Embryonic Stem Cells: and 
Introduction, 5 Human Fertility, 203-205 (2002). 
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embryos can also be created by somatic cell 
nuclear transfer (cloning). Cloning is a 
process whereby the nucleus of an adult cell 
is inserted into an enucleated oocyte to 
produce an embryo with DNA that matches 
that of the donor cell.10 In any case, the state 
of science is such that, although there have 
been developments as to the possibility of 
obtaining pluripotent human stem cells using 
alternate procedures not involving embryos,11 
it does not currently seem possible to isolate 
hESC without also destroying the embryos 
in which they are found.12 Indeed, stem cell 
technologies are still very much at a 
developmental stage.13 
10 The President’s Council on Bioethics, Human 
Cloning and Human Dignity: An Ethical Inquiry xxv, 
(The President’s Council on Bioethics 2002) (2002). 
11 For example: Kazutoshi Takahashi, Koji Tanabe, 
Mari Ohnuki, Megumi Narita, Tomoko Ichisaka, 
Kiichiro Tomoda & Shinya Yamanaka, Induction of 
Pluripotent Stem Cells from Adult Human Fibroblasts 
by Defined Factors, 131 Cell, 861-872 (2007); Junying 
Yu, Maxim A. Vodyanik, Kim Smuga-Otto, Jessica 
Antosiewicz-Bourget, Jennifer L. Frane, Shulan Tian, 
Jeff Nie, Gudrun A. Jonsdottir, Victor Ruotti, Ron 
Stewart, Igor I. Slukvin, James A. Thomson, Induced 
Pluripotent Stem Cell Lines Derived from Human 
Somatic Cells, 318(5858) Science, 1917-1920 (2007); 
Karen Kaplan, A Stem Cell ‘Milestone’, Los Angeles 
Times, November 21, 2007 available at http://www.
lat imes.com/news/nat ionworld/nat ion/ la-sci-
stemcells21nov21,0,2192969.story?coll=la-home-nation 
; Gina Kolata, Scientists Bypass Need for Embryo to Get 
Stem Cells, The New York Times, November 21, 2007, 
available at http://www.nytimes.com/2007/11/21/
science/21stem.html?_r=1&oref-slogin.
12 The President’s Council on Bioethics, supra note 
8, at 7-11; Star Lopez, The Children of Science: People, 
Property, or Something in Between?, UCLA School of 
Law Research Paper No. 06-16, 37 (2006) available at 
http://ssrn.com/abstract=891840. 
13 Douglas C. Wu, Ashleigh S. Boyd & Kathryn J. 
Wood, supra note 1, at 4525-4535; Anita Nador & Tina 
Loucaides, Stem Cells: Patents and Related Legal Issues 
B) Ethical Issues Surrounding hESC 
Research
For all its promises, there are also some 
important ethical concerns raised by 
embryonic stem cell research.14 Some argue 
that since the embryo’s status is identical, or 
at a minimum very similar, to that of the 
living person, and given the fact that hESC 
research necessarily entails the destruction of 
these entities, then such research ought not 
to occur. Thus, some hESC research opponents 
insist that the destruction of these embryos is 
equivalent to the destruction of human life 
because life begins when an egg and a sperm 
unite.15 However, a popular counter-argument 
points out that, in situations where stem cells 
are extracted from excess IVF embryos, were 
it not for hESC research, these embryos 
would ultimately be wasted: as these embryos 
would no longer be needed for purposes of 
assisted procreation, there would not be any 
other use for them other than disposal. In this 
case, it is argued that hESC research is a better 
alternative for the use of IVF embryos as 
compared to disposal. 16 Should the alternate 
(Bereskin & Parr 2002) (2002). Some of the fundamental 
questions that still need to be answered relate to how to 
maintain stem cells in their undifferentiated states and 
how to control differentiation once they have been 
extracted and isolated.
14 Rosario M. Isasi & Bartha M. Knoppers, Mind 
the Gap: Policy Approaches to Embryonic Stem Cell and 
Cloning Research in 50 Countries, 13 European Journal 
of Health Law, 9-26 (2006). 
15 Committee on the Biological and Biomedical 
Applications of Stem Cell Research, Stem Cells and the 
Future of Regenerative Medicine 44, (National Academy 
Press 2002) (2002); The President’s Council on 
Bioethics, supra note 8. 
16 Anne McLaren, Ethical and Social Considerations 
of Stem Cell Research, 414 Nature, 129-131 (2001). 
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procedures that do not require embryos in 
order to obtain pluripotent stem cells become 
viable, then this particular ethical concern 
would recede.17 
Other hESC research opponents are more 
specifically concerned with cloning in order 
to obtain hESC. In addition to the problem 
of destroying embryos, cloning raises issues 
such as the inherent discomfort with the idea 
of playing God, the physical and psychological 
safety of the cloned individual, and the 
“slippery slope” towards using cloning 
processes to create more humans.18
The abundance of literature demonstrates 
that these topics have been fiercely debated. 
However, whether one is in favour of or 
against stem cell research as it currently 
exists, it would seem that all stakeholders 
respect the great scientific potential stem cell 
studies have for human health.19
2. INTELLECTUAL PROPERTY 
RIGHTS AND STEM CELL 
RESEARCH
Human stem cell research, being a 
relatively new scientific field, the technologies 
concerned are often research tools, or 
building blocks for the development of 
clinically useful downstream products.20 Due 
17 Karen Kaplan, supra note 11.
18 Russell Korobkin & Stephen Munzer, supra note 
9, at 17-19.
19 Melissa Little, Wayne Hall & Amy Orlandi, 
Delivering on the Promise of Human Stem-Cell 
Research,  7(10) European Molecular Biology 
Organization, 1188-1192 (2006). 
20 John P. Walsh, Ashish Arora & Wesley M. Cohen, 
Research Tool Patenting and Licensing and Biomedical 
Innovation, in Patents in the Knowledge-Based 
to the upstream nature of these technologies, 
the expression “transfer of technology” rather 
than the term “commercialization” will be 
used when referring to the transmission of 
knowledge and inventions in the field of stem 
cell research.21 It is true that all scientific 
endeavours, whether upstream or downstream, 
could technically be “commercialized” given 
the fact that research, as a product of creative 
energies and monetary investments, is likely 
to add commercial value to the project in 
question.22 However, in view of the general 
public’s interest in the therapeutic potential 
of stem cell therapies, while commercial 
exploitation of upstream technologies can be 
an accessory goal, it is the sharing of this 
knowledge that should be the dominant 
objective due to the need to further develop 
this relatively new field of science. 
A comprehensive evaluation of the impact 
of the intellectual property protection system 
on the field of medical research would, of 
course, be impossible due to the absence of 
consensus regarding the criteria that should be 
used for such an evaluation and also due to the 
current lack of empirical evidence. The more 
modest goals of this paper are to consider 
whether existing data confirms, or conversely, 
refutes the claim that intellectual property laws 
interfere with technology transfer in human 
Economy, 285-287 (Wesley M. Cohen & Stephen A. 
Merrill eds., 2003) (2003); Stem Cell Network, Business 
is Good, 5(1) Stem Cell Network, 20 (2006).
21 Matthew Herder, Open Sourcing Stem Cells in 
Canada, 6, (2005) (unpublished manuscript issued from 
two conferences (Canadian Bioethics Society Annual 
General Meeting and the Stem Cell Network Annual 
General Meeting). 
22 Comité consultatif national d’éthique pour les 
sciences de la vie et de la santé, supra note 4, at 5-6. 
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stem cell research and to assess whether open 
modes of technology transfer would be helpful 
and practicable complements or alternatives 
to the current system.
A) Intellectual Property and Stem Cell 
Research
Stem cell research tools can be protected 
via a variety of different legal vehicles like 
contract law, trade secrecy, a sui generis 
regime, copyright, or, as is most often the 
case, a patent. Copyright and patents are 
forms of intellectual property and can be used 
to protect stem cell products depending on 
the nature of the technology. Due to the nature 
of most stem cell technologies, patents are 
the most common form of protection currently 
used in this field. 
Patent law is commonly justified by 
utilitarian principles: patent laws provide 
inventors with financial incentive to innovate, 
and thereby stimulate the development of 
industry for the benefit of all. In exchange for 
the public divulgation of their creations, 
patents give inventors exclusive rights, for a 
limited period of time, over the creation, use, 
and commercialization of their inventions23 
such that they may not only recoup the 
financial outlays made but also profit from 
them. By the same token, rather than having 
the invention shrouded in secrecy in order to 
protect the inventor’s interests, patents allow 
society to reap the medical and scientific 
benefits of the openly disclosed innovation.24 
23 Yann Joly, Open Source Approaches in 
Biotechnology: Utopia Revisited, 59(2) Maine Law 
Review, 386-390 (2007).
24 Id.
Therefore, the patenting of stem cell 
technologies is believed to be desirable 
because it balances the competing interests 
of the inventor (or more practically speaking, 
the entity providing financial support to the 
inventor and her research) and the public.
The development of stem cell technologies 
involves a significant amount of mental and 
financial commitment on the inventor’s 
part:25 among other tasks, she must run 
laboratories, manage clinical trials, and create 
stem-cell differentiation protocols.26 As an 
illustration of the outlays that are required in 
the field of stem cell research, it took more 
than 20 years to successfully isolate the first 
hESC27 and researchers are currently 
speculating that it could take up to 15 
additional years before hESC can be used for 
transplantation purposes.28 Moreover, the 
collecting of eggs for stem cell research 
purposes is extremely expensive. One article, 
commenting on the costs of doing diabetes 
related stem cell research, stipulated that :
To treat, for example, the 17 million diabetes 
patients in the US will require a minimum of 
850 million to 1.7 billion human eggs. 
Collecting 10 eggs per donor will require a 
minimum of 85 to 170 million women. The 
25 David B. Resnik, The Commercialization of 
Human Stem Cells: Ethical and Policy Issues, 10(2) 
Health Care Analysis, 130 (2002); Shamnad Basheer, 
Block Me Not: Are Patented Genes ‘Essential Facilities’?, 
1 University of Illinois Journal of Law, Technology and 
Policy, 55 (2005).
26 Sorapop Kiatpongsan, Intellectual Property and 
Patent in Stem Cell Research Era, 11 Journal of the 
Medical Association of Thailand, 1984 (2006).
27 Vicki Brower, Human ES Cells : Can You Build 
a Business Around Them?, 17 Nature Biotechnology, 
139-142 (1999). 
28 Id.
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total cost would be astronomical, at $100,000 
to $200,000 for 50 to 100 human eggs per 
each patient.29
Thus, given the therapeutic potential of 
stem cell research, but also the substantial 
amount of energy and financial investment 
required to develop these technologies, it is 
understandable that an inventor would want 
to have her inventions patented. 
Yet, it is not only privately funded scientists 
seeking compensation for the time and money 
invested in their research that are looking to 
patent. Academics also have an incentive to 
patent under legislation such as the US Bayh-
Dole Act, “which strongly [encourages] 
American universities to patent scientific 
discoveries made with public funds and partner 
with industry to commercialize them” in order 
to maximize medical and economic 
development.30 Moreover, contrary to popular 
belief, academics are not necessarily more 
inclined to share information in the name of 
scientific progress; rather this idea must be 
tempered due to evidence of competitive 
behaviour, animosity, and greed in academia 
sometimes leading to increased secrecy and 
patenting in research.31 Thus, both the private 
and public sectors have interests, however 
different they may be, in patenting stem cells 
and stem cells by-products. 
29 Robert Moffit, Kelly Hollowell, Phil Coelho & 
Honorable Dave Weldon, Federal Stem Cell Research: 
What Taxpayers Should Know (May 24, 2005), http://
www.heritage.org/Research/HealthCare/wm749.cfm 
(last visited June 30, 2007). 
30 Herder, supra note 21, at 9; Merrill Goozner, 
Innovation in Biomedicine: Can Stem Cell Research Lead 
the Way to Affordability? (2006), http://onthecommons.
org/node/837/ (last visited June 30, 2007).
31 Joly, supra note 23
B) An Outlook on Contemporary 
Knowledge Transfer Practices 
The pa tent  sys tem is  rooted  in 
contradiction: “the system aims to stimulate 
innovation by granting exclusive rights to 
the inventor who will then have the means 
to restrict the use and the perfecting of his 
invention by others”32. In other words, 
although the patents were intended to 
encourage the creation of knowledge for the 
benefit of the public, inventors can wield 
their exclusive rights and in practice prevent 
others from accessing their inventions by 
demanding high fees in exchange for the use 
of their inventions. Intellectual property 
rights, when enforced with too much zeal, 
can therefore slow the progress of science. 
Another connected reason for research 
delays is recent the proliferation of complex 
and invasive material transfer agreements 
(MTAs) among academic institutions and 
industry. MTAs are private contracts that 
govern the transfer of technologies, whether 
they are protected by intellectual property 
rights or not, for purposes of research or 
commercialization.33 Interestingly, although 
these designed to encourage scientific 
advancement by facilitating collaboration, 
these agreements may in fact be hindering 
progress on two levels. First, as MTAs 
become increasingly more convoluted to 
accommodate the reality of complex 
intellectual property rights, the negotiations 
between parties grow correspondingly more 
32 Id.
33 Victor Rodriguez, Material Transfer Agreements: 
Open Science vs. Proprietary Claims, 23(4) Nature 
Biotechnology, 489 (2005).
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difficult. The negotiating process is in fact 
so difficult that, in a recent study, scientists 
reported abandoning the transfer project 
altogether, to the detriment of science. 34 
What is also problematic is that when 
agreements are ultimately concluded, some 
MTAs contain such strict confidentiality and 
ownership provisions in favour of the 
provider,  that even if valuable new 
information is created through research on 
the provided materials, it cannot be freely 
circulated.35 Thus, similarly to the access to 
technology concerns that patents engender, 
MTAs can also prevent  the  t imely 
advancement of research by restricting the 
flow of information.
Some fear that this access to technology 
problem is exacerbated in light of the current 
patenting tendencies and the nature of stem 
cell technologies. It is suggested that, up until 
the 1970s, biomedical research conducted in 
universities was fuelled for the purpose of 
scientific progress rather than with a profit 
oriented corporate objective. 36 But, in the 
1970s, major scientific discoveries in the field 
of genetics as well as political pressures 
added a decidedly financial flavour to 
biomedical research. The biomedical industry 
had previously been limited in its range of 
34 Alan Dove, When Science Rides the MTA, 110(4) 
The Journal of Clinical Investigation, 425-426 (2002).
35 Rodriguez, supra note 33, at 489.
36 Arti K. Rai, Open and Collaborative Research: 
A New Model for Biomedicine, in Intellectual Property 
Rights in Frontier Industries 131-140 (Robert W. Hahn 
ed., AEI-Brookings Press) (2005); Joly, supra note 23, 
at 392. However this altruistic portrait of academics must 
be nuanced by newly uncovered evidence of scientists 
actively preventing the open dissemination of their 
discoveries for a variety of reasons such as competition, 
animosity, and greed. 
saleable products due to the relatively 
undeveloped state of biomedical knowledge. 
However, the scientific breakthroughs of 
recombinant DNA and monoclonal antibodies 
effectively spurred the prospective for new, 
marketable drugs and technologies. This 
pecuniary incentive underlying biomedical, 
and biotechnological research more generally, 
strengthened the urge to patent scientific 
inventions in order to maximize their 
profitability and thereby create interest from 
the private sector.37 
Moreover, in the landmark 1980 case, 
Diamond v. Chakrabarty, the US Supreme 
Court allowed a patent over a bacterium 
capable of breaking down crude oil. To 
support its ruling, the court quoted the 1952 
Patent Act Committee Reports by affirming 
that “anything under the sun that is made by 
man” was patentable.38 This case effectively 
vindicated the patentability of life forms 
including certain biotechnologies in the US. 
Then, in 1980, political pressures in the US 
provoked the enactment of the Bayh-Dole Act 
“which strongly encouraged American 
universities to patent scientific discoveries 
made with public funds and partner with 
industry to commercialize them”.39 These 
American legal developments were eventually 
adopted by the international scientific 
community such that the patenting of 
biotechnological inventions, assuming they 
meet standard patent criteria, is now perceived 
as both legally appropriate and desirable.  
Taken together, these scientific, social, 
and legal developments have largely 
37 Rai, supra note 36. 
38 447 U.S. 303 (1980). 
39 Herder, supra note 21, at 9.
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contributed to the current predilection for 
act ively patenting biotechnological 
inventions, including stem cell technologies, 
instead of placing the knowledge in the 
public domain. 
Access to technology concerns may be 
further aggravated due to the specific 
logistical set-up of the field of stem cell 
research. First, it should be noted that stem 
cell research, like many other scientific 
research fields, advances incrementally.40 
Secondly, since stem cell research mainly 
involves the development of foundational 
technologies into downstream ones, then 
relying on upstream inventions is necessary 
in order to create new knowledge in this 
research field. These two particular features 
of stem cell research (cumulativeness and 
newness) give the patent-related problem 
of access to technology additional levels 
of complexity. 
The Tragedy of the Anticommons
In the field of biotechnological research, 
Heller and Eisenberg have argued that the 
“tragedy of the anticommons” is a possible 
40 Rai, supra note 36, at 137; Shamnad Basheer, 
supra note 25; Stem Cell Network, supra note 20. We 
must also consider that: “[over] the past twenty years, 
fundamental changes have revolutionized the science 
and technology underlying product and process 
innovation in drugs and the development of medical 
therapies and diagnostics. Advances in molecular 
biology have increased our understanding of the genetic 
bases and molecular pathways of diseases. Automated 
sequencing techniques and bioinformatics have greatly 
increased our ability to transform this understanding into 
patentable discoveries that can be used as targets for 
drugs development […] The consequences of these 
changes is that progress in biomedical research is now 
more cumulative.” (Walsh, Arora & Cohen, supra note 
20, at 285-289) 
threat to the advancement of this scientific 
sector. When upstream products and 
processes, as essential building blocks for 
downstream innovation, are patented, would-
be inventors of downstream products must 
go through the potentially lengthy and 
expensive process of obtaining several 
different licences in order to progress in their 
research endeavours.41 This process of 
obtaining the consent of several different 
rights holders may deter downstream 
inventors altogether thereby preventing the 
transfer of useful technologies and 
subsequently inhibiting useful development. 
However, despite these admonitions, several 
studies have shown that a situation of 
anticommons has not materialised in 
biotechnology as of yet because researchers 
have made use of “working solutions” such 
as “taking licences (i.e., successful contracting), 
inventing around patents, going off-shore, 
the development and use of public databases 
and research tools, court challenges and 
[infringement]” to progress in their research.42
More importantly, the field of stem cell 
research does not seem particularly susceptible 
to the anticommons threat. As it will soon be 
discussed, stem cells and stem cell by-
products are currently protected by a few, 
broad patents rather than a number of 
41 Michael A. Heller & Rebecca S. Eisenberg, Can 
Patents Deter Innovation? The Anticommons in 
Biomedical Research, 280 Science, 698-7011 (1998); 
Goozner, supra note 30.
42 Walsh, Arora & Cohen, supra note 20, at 331.A 
study conducted in 2005 also denied the reality of an 
anticommons in research fields where patenting is common 
(John P. Walsh, Charlene Cho & Wesley M. Cohen, Patents, 
Material Transfers and Access to Research Inputs in 
Biomedical Research at http://www.uic.edu/~jwalsh/
NASreport.html (last visited June 30, 2007).
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overlapping patents.43 But, notwithstanding 
the questionable existence of an anticommons 
in this scientific field, patenting stem cell 
technologies can still present a two-fold 
dilemma for the development of stem 
cell research.
Patenting Key Upstream Inventions
Firstly, progress could be hindered if the 
use of patented research tools is a precondition 
for the development of further downstream 
inventions.44 If a scientist can choose to use 
one of a number of different research tools to 
reach a desired result, then the fact that a 
limited number of these research tools are 
patented will not slow her work down; this 
is because there are other unpatented research 
tools that she could use without having to lose 
time or money negotiating licences. It follows 
that if a particular upstream discovery is a 
necessary building block for a subsequent 
innovation, then patenting the former 
discovery may thwart the timely development 
of that science. This concern echoes loudly 
in stem cell research due to the interdependent 
nature of this particular field.45
43 Walsh, Arora & Cohen, supra note 20, at 308
44 Timothy Caulfield, Robert M. Cook-Deegan, F 
Scott Kieff & John P. Walsh, Evidence and Anecdotes: 
an Analysis of Human Gene Patenting Controversies, 
24 Nature Biotechnology, 1091-1094 (2006); Walsh, 
Arora & Cohen, supra note 20, at 334; Matthew Herder, 
Proliferating Patent Problems with Human Embryonic 
Stem Cell Research?, 3(1-2) Journal of Bioethical 
Inquiry, 71 (2006); Basheer, supra note 25; Lori 
Andrews, Jordan Paradise, Timothy Holbrook & 
Danielle Bochneak, When Patents Threaten Science, 
314(5804) Science, 1395-1396 (2006). 
45 Rai, supra note 36, at 137; Walsh, Arora & Cohen, 
supra note 20, at 289; Basheer, supra note 25. 
However,  the threat  of  arrested 
development must be mitigated in light of 
recent studies. It has been suggested that stem 
cell research is not as cumulative as once 
believed because new methods could 
potentially be used as different “pathways” 
for achieving a same result.46 For example, 
James Thomson, a researcher at the University 
of Wisconsin, was the first to isolate hESC 
in 1998. He was awarded two patents which 
he then assigned to the Wisconsin Alumni 
Research Foundat ion (WARF),  the 
organization that provides financing for 
scientific research at the University of 
Wisconsin.47 It was widely believed that these 
two patents on stem cell derivation 
technologies effectively blocked major 
branches of stem cell research because the 
use of these two inventions were thought to 
be necessary for the differentiation processes 
of hESC.48 However, methods such as 
“parthenogenesis, embryo biopsy, cellular 
fusion, altered nuclear transfer” have recently 
been touted as alternate, unpatented, processes 
for deriving hESC49 such that the WARF 
patents may not necessarily be needed to 
further develop hESC technologies.
Moreover, the concern that stem cell 
research will be delayed due to patented 
upstream inventions should again be 
46 K.S. Taymor, C.T.Scott & H.T. Greely, The Paths 
Around Stem Cell Intellectual Property, 24(4) Nature 
Biotechnology, 411-413 (2006).
47 Walsh, Arora & Cohen, supra note 20. 
48 John Simpson, The Missing Link in Stem-cell 
Research: Op-Ed Commentary in the Sacramento Bee 
(July 2, 2006), http://www.consumerwatchdog.org/
co/?postId=6532 (last visited June 30, 2007). 
49 Taymor, Scott & Greely, supra note 46. 
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questioned because the therapeutic capacity 
of stem cells derives not only from human 
embryonic stem cells, but from stem cells 
originating from the born alive individual as 
well.50 Since positive medical results can be 
achieved using both types of stem cells, then 
perhaps the patenting of a limited number of 
stem cells or stem cell by-products will not 
create such an acute problem for the 
advancement of stem cell research. Therefore, 
it is possible that the field of stem cell 
research can still progress despite the 
patenting of a few key inventions. 
Patent Scope
Broad patents over stem cell technologies 
present yet another potential barrier to the 
advancement of stem cell research: a patent 
that protects the use of an invention in an 
overbroad manner could block subsequent 
inventors from engaging in any number of 
research activities that are covered by the 
initial patent. In other words, patent claims 
that do not accurately describe the exact scope 
of the invention may grant exclusive rights 
over a wide area of research thus “blocking 
o f f  w h o l e  a r e a s  o f  r e s e a r c h  a n d 
development”.51 
WARF’s patent No. 5,843,780 claimed 
primate embryonic stem cells, primate 
embryonic stem cell lines derived from the 
former original stem cells, and the process 
used to create them.52 WARF’s patent No. 
50 Walsh, Arora & Cohen, supra note 20. 
51 Dianne Nicol, Cooperative Intellectual Property 
in Biotechnology, 4(1) SCRIPT-ed, 137-139 (2007), 
available at http://www.law.ed.ac.uk/ahrc/script-ed/
vol4-1/nicol.pdf (last visited June 30, 2007). 
52 Taymor, Scott & Greely, supra note 46, at 411.
6,200,806, which claimed the same but for 
human embryonic stem cells, was similarly 
broad in scope.53 Both these patents expire in 
2015. To put it simply, until 2015, “[this] 
means that WARF essentially claims 
ownership rights to all hESC and downstream 
products, regardless of how they are derived 
[…] it is likely that any attempts at 
commercialization of a product based on hES 
cells without WARF’s consent will lead to an 
infringement lawsuit.”54 
But, there are two important reasons 
why a researcher would be reticent to 
obtaining a licence to WARF’s patents. 
Firstly, despite WARF’s commitment to 
grant non-commercial use licences at a low 
fee,55 academics will probably not have 
the incentive to avail themselves of this 
opportunity because of existing legislation 
(for example, the Bayh-Dole Act) “which 
strongly [encourages] American universities 
to patent scientific discoveries made with 
public funds and […] to commercialize 
them”.56  In addition, in light some American 
caselaw,57 academic research involving 
patented stem cell technologies now carries 
greater risks of patent infringement due to the 
narrowed scope of the research exception in 
American law. Thus, scientists who would 
like to make use of the WARF non-commercial 
53 Munzer &Korobkin, supra note 9, at 45-46.
54 Sander Rabin, The Gatekeepers of hES Cell 
Products, 23 Nature Biotechnology, 817 – 819 (2005).
55 Jeanne F. Loring & Cathryn Campbell, Intellectual 
Property and Human Embryonic Stem Cell Research, 
311(5768) Science, 1716-1717 (2006).
56 Herder, supra note 21, at 9. 
57 Madey v. Duke University, 307 F.3d 1351 (Fed. 
Cir. 2002); Jennifer Miller, Sealing the Coffin on the 
Experimental Use Exception, 12 Duke Law and 
Technology Review (2003). 
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use licence must tread carefully in order to 
avoid patent infringement. However, as 
mentioned above, there are legislative 
pressures to patent the results of strictly 
academic research. By consequence, 
academics wanting to patent any of their 
WARF-related inventions would be obliged 
to concede these commercial rights to WARF 
pursuant to the terms of the non-commercial 
use licence.58 This chain of restrictions on 
academic research could ultimately discourage 
scientists from obtaining non-commercial 
WARF licences altogether.
Although WARF has announced that as 
of January 2007, it has granted over 350 
academic licences,59 one would reasonably 
assume that these figures could be higher but 
for the strictly non-commercial character of 
the licence. Therefore, the scope of the 
WARF patent is likely having the effect of 
suppressing hESC academic research.60
Secondly, it is evident that commercial 
researchers could also be deterred from any 
hESC research due not only to the negotiation 
delays but also to the high costs associated 
with obtaining licences from WARF.61 In fact, 
58 Jennifer Washburn, The Legal Lock on Stem 
Cells: Two Patents that Cover Key Research Areas are 
Setting Back Science, Los Angeles Times, April 11, 2006, 
available at http://www.newamerica.net/publications/
articles/2006/the_legal_lock_on_stem_cells (last visited 
June 30, 2007). 
59 Wisconsin Alumni Research Foundation, WARF 
Changes Stem Cell Policies to Encourage Greater 
Academic, Industry Collaboration (January 23, 2007), 
http://www.warf.org/news/news.jsp?news_id=209 (last 
visited June 30, 2007).
60 Loring & Campbell, supra note 55 at 1716; 
Washburn, supra note 58. 
61 Nicol, supra note 51, at 140; Constance Holding, 
U.S. Patent Office Casts Doubt on Wisconsin Stem Cell 
Patents, 316(5822) Science, 182 (2007). 
a commercial licence costs up to 125, 000 
USD and then an additional 40, 000 USD per 
year to retain the licence.62 For young start-
ups focussed on the development of stem cell 
technologies, these fees may simply be too 
heavy to bear.63 The result is that there will 
be less stem cell-related research initiatives 
being launched than there potentially could 
be, were the licensing procedures less 
complicated and less costly.64 Indeed, authors 
have noted that potential company-builders 
vying for a piece of the stem cell market have 
been dissuaded due to the difficulty of 
“[accessing] embryonic stem cells at a 
reasonable price from the Wisconsin Alumni 
Research Foundation”.65 
The Wilmut patents are another example 
of how the scope of a patent may negatively 
affect the progress of stem cell research. 
Although these patents claim several cloning 
processes for the production of non-human 
stem cells, they may still inhibit the 
development of hESC research because it has 
been suggested that “the series of techniques 
that they describe are one likely means of 
producing hES cells by [cloning]”.66 Taking 
into consideration the supposition that the 
WARF patent protects arguably all hESC and 
their downstream products, and assuming that 
the Wilmut patents protect one important 
method for cloning hESC, then there are 
perhaps very limited ways for producing, 
differentiating, and reaping the commercial 
benefits of hESC without using, and by 
62 Loring & Campbell, supra note 55 at 1717. 
63 Washburn, supra note, 58. 
64 Rai, supra note 36, at 135.
65 Merrill Goozner, supra note 30. 
66 Taymor, Scott & Greely, supra note 46, at 411.
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consequence paying for the use of, one of the 
above patents. 
To summarize, with respect to the field of 
stem cell research, the patent system’s main 
negative consequence of limiting access to 
technology is manifested in two different 
ways: the patenting of foundational research 
tools and the overly broad scope of stem cell 
patents both raise significant issues of access 
to technology and could therefore justify the 
need for alternatives to the standard business 
model of patenting stem cell technologies. 
The academic controversy surrounding the 
WARF patents suggests that the issue of 
overly broad patents is the most compelling 
argument against the patenting of stem 
cell technologies. 
3. STEM CELL RESEARCH 
PRACTICES IN LIGHT OF THE 
WARF PATENTS
A) Stem Cell Research in the US 
The American legal community has 
reacted strongly to WARF’s assertion of 
property rights over all human stem cells and 
the techniques used to isolate them. There is 
an impressive amount of literature that 
purports that the patents may be impeding 
stem cell research in the US.67 However, there 
seem to be nearly as many articles that 
67 For example: Cathy Tran, WARF Stem Cell 
Patents Challenged (October 11, 2006), http://www.
the-scientist.com/news/display/25037/ (last visited June 
30, 2007); Alison McCook, Stem Cell Patents Loosened 
(January 23, 2007), http://www.the-scientist.com/news/
display/43099/ (last visited June 30, 2007); Michael C. 
Mireles Jr., States as Innovation System Laboratories: 
California, Patents, and Stem Cell Technology, 28 
Cardozo Law Review, 1133 (2006).
describe methods that are currently being 
used, or could be used, to counter the effects 
these patents may have on the development 
of research. For example, it has been claimed 
that, instead of negotiating licences with 
WARF in order to pursue research, American 
scientists “have sent research monies abroad 
where they can avoid paying royalties to 
WARF” 68.  Also,  as  in  the  f ie ld  of 
biotechnological research more generally, 
stem cell scientists could be using other 
“working solutions”69 to pursue their work. 
Thus, scientists are not only criticizing the 
WARF patents but are also proactively 
attempting to circumvent the potential 
negative effects they may be having on the 
development of research. 
The measures taken to dodge the effects 
of the WARF patents do not end there: not 
only has stem cell research been carried 
outside of the US, but legal challenges have 
also been officially filed against the validity 
of these patents.70 In July of 2006, several 
non-profit organizations, namely the 
Foundation for Taxpayer and Consumer 
Rights and the Public Patent Foundation, 
called on the US Patent and Trademark Office 
(PTO) to “re-examine and revoke” the WARF 
patents based on the allegation that the 
processes used to isolate the human stem cells 
were obvious in light of the existing 
knowledge and, by consequence, not 
68 Public Patent Foundation, Groups Challenge 
Stem Cell Patents that Loot Taxpayer Funds and Force 
Research Overseas: University of Wisconsin Affiliate 
Claims Rights to all Embryonic Stem Cells Used for 
Research (July 18, 2006), http://www.pubpat.org/
warfstemcellsfiled.htm (last visited June 30, 2007). 
69 See section 2B
70 Tran, supra note 67. 
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patentable.71 In April 2007, the PTO found 
that the patents were indeed obvious, but 
the WARF has since appealed the merits of 
this decision.72 
The theoretical criticism that WARF has 
received and the research community’s 
proactive attempts to evade the research-
restricting effects of the WARF patents 
suggest that  there is  an unyielding 
determination to continue doing stem cell 
research despite the practical obstacles that 
the WARF patents may present. In fact, even 
though this field is still quite new and even 
if not all researchers automatically seek 
patent protection for their inventions, as of 
April 2007, the PTO will have granted 1724 
patents and will have received 3711 patent 
applications “covering any and all ‘uses, 
methods, or compositions involving human 
or animal stem cells’ ”.73 These numbers 
again suggest that, despite the disincentives 
to research that the WARF patents may create, 
the scientific community is nonetheless 
interested in pursuing stem cell research. 
However, the fact that researchers are trying 
to find alternative solutions bears witness to 
the negative effect of the WARF patents on 
71 Constance Holding, Prominent Researchers Join 
the Attack on Stem Cell Patents, 317 Science, 187 (2007). 
72 Alison McCook, Key Stem Cell Patents Rejected 
(April 3, 2007), http://www.the-scientist.com/news/
home/53051/ (last visited June 30, 2007) ; Erika Check, 
Patenting the Obvious, 447 Nature, 16-17 (2007); Ryan 
J. Foley, Wis. Foundation Challenges Decision to Reject 
Stem Cell Patents (June 1, 2007), http://www.
gazetteextra.com/stemcellpatents060107.asp (last 
visited June 30, 2007). 
73 Karl Bergman & Gregory D. Graff, The Global 
Stem Cell Patent Landscape: Implications for Efficient 
Technology Transfer and Commercial Development, 
25(4) Nature Biotechnology, 420 (2007). 
research. As such, in order to sustain this high 
level of interest in stem cell research, it is 
important to create a research environment 
that would not further hinder the field’s 
timely development.
B) Stem Cell Research in Europe
In Europe, there are legislated bars to 
patentability based on morality in the 
Directive on the Legal Protection of 
Biotechnological Inventions 98/44/EC (the 
Directive). Although the interpretation of the 
Directive’s morality clause is far from being 
uniform in all European jurisdictions, there 
are nonetheless two watershed European 
Patent Office (EPO) decisions that discuss 
the patentability of stem cell technologies. In 
the University of Edinburgh and the WARF 
cases, the EPO ruled that since inventions 
involving hESC necessarily required the use 
of embryos, then these claims were not 
patentable pursuant to the Directive74 which 
states that “[…] European patents shall not 
be granted in respect of biotechnological 
inventions which, in particular, concern the 
following: […] (c) uses of human embryos 
for industrial or commercial purposes […]”75 
Although it would seem that multipotent and 
unipotent stem cells that are extracted directly 
from the adult are not caught by this Rule, 
hESC per se and the processes used for their 
isolation are unpatentable.76 Unlike the 
74 Nador & Loucaides, supra note 13.
75 Directive 98/44/EC of the European Parliament 
and of the Council of 6 July 1998 on the Legal Protection 
of Biotechnological Inventions, art. 6(c), 1998, O.J. EPO; 
Munzer & Korobkin, supra note 9, at 56.
76  Joe Vanden Plas, WARF Stem Cell Patent Faces 
Long and Winding Road (May 31, 2006), http://
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American context, it is not WARF’s patent, 
in and of itself, that could be problematic for 
the advancement of stem cell research. 
Rather, given the research incentives that 
patents create, it is the broad interpretation 
of the morality clause in light of the WARF 
patent that may be creating a disincentive to 
undertake such research. Thus, it is not just 
the granting of overly broad patents that could 
hinder progress in the field of stem cell 
research because the outright barring of stem 
cell technologies from patentability is equally 
capable of slowing such research.
The EPO’s interpretation of the morality 
clause has caused some researchers to employ 
creative wording techniques in their stem cell 
related patent applications in order to ensure 
the validity of their claims: potential patent 
holders have made sure not to extend their 
claims to hESC by, for instance, adding the 
term “nonhuman” before “embryonic stem 
cell”.77 Another way of circumventing the 
ruling of the University of Edinburgh and 
WARF cases is to funnel patent claims 
through national patent offices rather than the 
EPO in order to obtain protection for hESC 
technologies. 78 These state patent offices 
have the authority to grant patents that are 
wistechnology.com/article.php?id=3006 (last visited 
June 30, 2007). Note that Both the University of 
Edinburgh and the WARF have appealed these decisions 
based on the argument that only the use of embryos as 
raw materials are excluded from patentability. This 
would mean that while embryos themselves are 
unpatentable, patent claims that make use of them at 
some stage are valid. 
77 G. Porter, A. Denning, A. Plomer, J. Sinden & P. 
Torremans, The Patentability of Human Embryonic Stem 
Cells in Europe, 24(6) Nature Biotechnology, 
654 (2006).
78 Id.
valid within their respective countries.79 
Scientists hope that countries’ individual 
interpretations of the European Patent 
Convention will be more lenient than the 
EPO’s with respect to the patentability of 
hESC technologies.80 Thus, the EPO’s 
interpretation of the morality clause might 
not necessarily cause scientists to lose interest 
in stem cell research. Instead, it has simply 
caused the research community to make use 
of alternate routes for acquiring protection 
for hESC technologies.
Thus,  regardless of the suggestion that 
the University of Edinburgh and the WARF 
cases may be disincentives to research, the 
existence of alternate patenting strategies 
suggests that the motivation to engage in stem 
cell research is still obviously present. 
Moreover, as of April 2007, the EPO will 
have granted 421 patents and received 
another 560 patent applications “covering any 
and all ‘uses, methods, or compositions 
involving human or animal stem cells’ ”.81 
Thus, similarly to the American context, the 
process of technology transfer must be low 
cost and uncomplicated in order to maintain 
this momentum in the development of stem 
cell research. 
79 Vanden Plas, supra note 76. 
80 UK Intellectual Property Office, Inventions 
Involving Human Embryoninc Stem Cells, http://
www.ipo.gov.uk/patent/p-decisionmaking/p-law/
p-law-notice/p-law-notice-stemcells.htm (last visited 
June 30, 2007). For example: The UK Patent Office 
in particular has issued a Practice Notice to the effect 
that pluripotent hESC-related technologies are 
patentable (provided they meet all other patentability 
criteria) because they do not have the potential to 
develop into a full human being like totipotent stem 
cells do.
81 Bergman & Graff, supra note 73.
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C) Stem Cell Research in Canada
Canada’s stem cell research regulatory 
framework is comparatively permissive 
because there seems to be only one bright line 
prohibition: all forms of cloning are prohibited. 
All other stem cell research practices, 
although highly regulated by various 
legislative documents, are tolerated.82 
However, despite the theoretical possibility 
of patenting stem cells, in practice, the 
Canadian Intellectual Property Office (CIPO) 
has yet to grant the WARF patents.83 One 
author has noted that, should these patents be 
granted, the stem cell research-friendly 
environment that researchers currently 
benefit from is likely to disappear: “Canadian 
researchers’ unfettered freedom to pursue 
certain avenues of stem cell research is in 
danger” because WARF’s patents are expected 
to protect hESC per se and just about all 
related downstream inventions.84 Practically 
82 Canadian Biotechnology Advisory Committee, 
Patenting of Higher Life Forms and Related Issues: 
Report to the Government of Canada Biotechnology 
Ministerial Coordinating Committee (June 2002), http://
cbac-cccb.ca/epic/site/cbac-cccb.nsf/en/ah00188e.
html#sec2b (last visited June 30, 2007); Assisted Human 
Reproduction Act, S.C. 2004, c.2, available at http://
www.canlii.org/ca/sta/a-13.4/whole.html; Canadian 
Institutes of Health Research, Natural Sciences and 
Engineering Research Council of Canada, Social 
Sciences and Humanities Research Council of Canada, 
Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Humans 9.4, (Public Works and 
Government Services Canada 2005) (1998 (with 2000, 
2002 and 2005 amendments)); Canadian Institutes of 
Health Research, Updated Guidelines for Human 
Pluripotent Stem Cell Research (June 28 2006), 
http://www.cihr-irsc.gc.ca/e/31488.html (last visited 
June 30, 2007). 
83 Canadian Intellectual Property Office, Patents 
Database, http://patents1.ic.gc.ca/fcgi-bin/patquery_eo_
el (last visited June 30, 2007). 
84 Herder, supra note 21. 
speaking, “if the blurred line between 
commercial and non-commercial research is 
transgressed without WARF’s prior 
permission, an action for patent infringement 
is likely to follow”.85 Much like what is 
currently being discussed in American 
academic circles, the WARF patents are seen 
as potential threats to the timely progress of 
stem cell research because of the scope of 
protection awarded to WARF.
However, if this is the case, then if/when 
the WARF patents are awarded, Canada is 
likely to follow the Americans’ lead in 
resolving problems of patent scope. As the 
Americans have done, Canadians may engage 
in proactive attempts to circumvent the use 
of the WARF patents to continue stem cell 
research by conducting research overseas 
where WARF has not yet been granted 
exclusive rights over hESC or by mounting 
legal challenges to the validity of the 
Canadian WARF patents. Moreover, in light 
of the relatively liberal structure governing 
stem cell research in Canada, researchers may 
perhaps pursue these WARF avoidance 
measures even more aggressively than 
American researchers to re-establish their 
freedom of scientific inquiry. Thus, effective 
technology transfer processes must be 
elaborated to ensure that broad patents on 
upstream stem cell technologies such as 
WARF’s do not hinder this anticipated 
enthusiasm for research.
In short, since the use of patent law is 
currently the most widespread way of 
protecting the interests of inventors, then 
researchers must address the potential 
difficulties associated with patent law 
85 Id. 
Revista da Faculdade de Direito - UFPR, Curitiba, n.47, p.101-139, 2008.
117
(ethical, philosophical, legal, and otherwise) 
in order to effectively continue their research. 
What remains to be explored is the extent to 
which open and collaborative models of 
technology transfer can be appropriate 
alternatives or complements to the patent 
system in the field of biotechnology.
4. ORIGINS OF OPEN SOURCE 
Open models of collaboration take root 
in the computer programming concept of free 
software. In the 1960s and 1970s, a “hacker” 
culture developed whereby technicians 
tended to freely exchange software and 
source codes, codes that humans use to read 
and modify software.86 Then, in the 1980s, 
the industry’s focus shifted to privatization 
with the advent of new and more powerful 
computers: computer firms started protecting, 
until then, uncopyrighted software, thereby 
restricting the possibility of free duplication. 
In addition, private companies withheld the 
distribution of source codes and subjected 
end-users to non-disclosure agreements 
whereby the software transferred could not 
be shared or modified.87 Thus, the increasingly 
proprietary mindset of the 1980s computer 
programming community put the “hacker” 
cooperative ethos under pressure. 
In response to this ideological shift, 
Richard Stallman decided to create a “free” 
operating system, the key piece of software 
86 Rai, supra note 36, at 137. 
87 Geoff Mulgan, Tom Steinberg & Omar Salem, 
Wide Open: Open Source Methods and Their Future 
Potential 12, (Demos) (2005); Richard Stallman, The 
GNU Operating System and the Free Software 
Movement, in Open Sources: Voices from the Open 
Source Revolution (O’Reilly Media, Inc) (1999); 
computers use to run. This software, called 
GNU, was released under a GNU Public 
Licence (GPL) that allowed people to run, 
copy, modify, improve, and redistribute the 
software at will (i.e. access to source codes 
was permitted).88 This GPL, also commonly 
referred to as a classic “copyleft”, also 
required that if modifications were made to 
the program, the modified version must be 
published under the same conditions as the 
original software.89 Thus the copyleft is, in 
direct opposition to a copyright, created to 
ensure that users have the “freedom” to 
duplicate and improve a program.90 
Unsurprisingly, the business community’s 
response to Stallman’s free software concept 
was lukewarm due to the movement’s total 
rejection of exclusively owned software. By 
consequence, “open source” rhetoric started 
being used to appeal to a more commercial 
audience by drawing attention away from the 
moral “sharing” aspect of free software, but 
retaining the concept of freedom to run, copy, 
and modify software. 91 The “Open Source 
Initiative” was therefore launched to promote 
essentially the same principles as free 
software, but not under the moral rubric of 
sharing and community.92 
88 Joly, supra note 23; Mulgan, Steinberg & Salem, 
supra note 87, at 13; Stallman, supra note 87.
89 Josh Lerner & Jean Tirole, The Economics of 
Technology Sharing: Open Source and Beyond, 19(2) 
Journal of Economic Perspectives, 99 (2005). 
90 Stallman, supra note 87. The “free software” 
movement was founded on the assumption that “the 
proprietary software social system […] is antisocial, it 
is unethical, […] it is simply wrong.” 
91 Herder, supra note 21, at 26-27; Joly, supra note 
23, at 392.
92 Stallman, supra note 87; Herder, id. 
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There are two benefits of open source 
projects that are most commonly seized upon 
to justify its use in the field of computer 
programming: open source projects can 
generate high-quality output and at a low 
cost.93 Firstly, the work produced is of good 
quality because participants are able to vet 
each other’s contributions such that flaws and 
can be effectively and quickly weeded out. 
Eric Raymond has been quoted a number of 
times on this matter: “given enough eyes, all 
bugs are shallow”.94 In fact, several studies 
that compared the technical aspects of open 
source software such as Linux, Apache, and 
GCC with closed source software found that 
the former were technically superior.95
The second point that is often brought up 
to justify the use of open source projects is 
that it can produce results at a low price. To 
obtain open sourced software (and thereby 
participate in the software improvement 
process), a participant need only have access 
to a computer and internet access. Then, 
beyond these basic costs, the acquisition of 
the software costs only what the copyleft 
licensing fees, if any, cost. For instance, 
obtaining Linux software costs nothing 
beyond the basic outlays of a computer and 
an internet connection.96 In addition, authors 
have identified other strengths of open source 
software such as transparency, existence of a 
legal structure and an enforcement mechanism, 
93 Rai, supra note 36, at 138; Mulgan, Steinberg & 
Salem, supra note 87 at 16ff. 
94 For example: Mulgan, Steinberg & Salem, supra 
note 87, at 20. 
95 Rai, supra note 36, at 139.
96 Mulgan, Steinberg & Salem, supra note 87, at 17. 
incrementalist, presence of powerful non-
monetary incentives.97
The drawbacks of open source are not as 
widely discussed as the advantages, but 
academics have nevertheless briefly noted a 
few.98 For example, open source projects may 
be susceptible to “minority capture” because 
they are vulnerable to being used to channel 
a group’s interests. Because these projects 
allow anyone to access them, any organized 
lobbyist faction would be able to manipulate 
and distribute the software for its own 
purposes. Also, there is the risk of “diversion 
and dissension”: because open source projects 
allow anyone to access them, they may suffer 
from contradictory contributions. Third, there 
is restricted access to funding. Open source 
97 Mulgan, Steinberg & Salem, supra note 87, at 
23ff; Rai, supra note 36, at 145ff.
Transparency: open source projects thrive on being 
open about their internal functioning. By consequence, 
contributors are aware of how all innovation is created.
A legal structure and enforcement mechanism: 
copyleft ensures that others cannot appropriate the work 
of others for themselves because it requires that any 
improvements made to the open sourced software be 
made available. Thus, participants will not be deterred 
from contributing their ideas. 
Incrementalist: improvements to software can be 
made by anyone, with any type of background. All 
modifications, no matter how small, contribute to the 
ongoing improvement process. 
Powerful non-monetary incentives: participants in 
open source projects are often motivated non-monetary 
factors. For instance, they will contribute because of the 
desire to be recognized and respected for their work. Or, 
they may contribute because they need a computer 
program to accomplish a specific task and the easiest 
and cheapest way to achieve that goal is to modify open 
source software.
98 Stephen Shankland, Is Open Source Fading 
Away? (November 21, 2001) http://www.zdnet.com.
au/news/software/soa/Is-open-source-fading-away-
/0,130061733,120261963,00.htm (last visited June 
30, 2007).
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projects have difficulty with attracting 
investment because the “goods” (the source 
codes) are made available to anyone who 
wants them. Fourth, it is believed that without 
an initial temporary monopoly over a product, 
nobody would have the incentive to develop 
it because the investments required to 
successfully market the good outweigh the 
potential benefits of open sourcing it. Note 
that this is the classic argument used to justify 
the patenting of inventions. Fifth, some argue 
that good ideas need to be isolated in order 
to thrive. Directed criticism in an open source 
project could have the effect of eliminating 
a good idea that was perhaps not yet fully 
developed.99 Finally, open projects may have 
a reduced ability for generating revenues 
from main products. Instead of purchasing 
propertied computer programs, consumers 
can simply copy them due to the open 
availability of source codes. This in turn can 
decrease a computer company’s revenues.100 
However, it should be noted that this decrease 
could be offset by the company’s ability to 
increase its revenues from complementary, 
and propertied, goods and services.101
Despite these weaknesses, given the 
steadily increasing number of open source 
projects being launched in the technology 
context, it would nonetheless seem that 
the strengths of open source eclipse the 
weaknesses. For instance, in 2005, 91,000 
such projects were recorded and authors note 
that this number continues to grow today. 102 
99 Mulgan, Steinberg & Salem, supra note 87, at 23ff. 
100 Shankland, supra note 98. 
101 Joly, supra note 23, at 400.
102 Herder, supra note 21, at 28.
Although software is the most obvious 
use of open source, the principles that 
underlie the open source method have 
increasingly been adapted to other areas of 
invention.103 What remains to be seen is 
whether such open source notions can be 
adapted to the field of biotechnology, 
generally, and to stem cell research, in 
particular. It should also be noted that since 
the expression “open source” can only 
properly be used in connection with source 
codes (i.e. software),104 the authors will refer 
to the adaptation of the open source method 
to other fields of knowledge as “open models” 
of technology transfer.
5. OPEN MODELS IN 
BIOTECHNOLOGY
A) Why Use Open Models in Biotechnology?
Biotechnology is a cumulative science 
and in order for this field to progress, 
researchers must have access to a spectrum 
of “enabling technologies”105 or upstream 
inventions. But, the patenting of key upstream 
inventions and overly broad patent claims 
may hinder downstream innovation. This 
means that the hindrance to the advancement 
of biotechnology lies in the tension between 
downstream inventors who need access to 
enabling technologies on the one hand, and 
103 Rai, supra note 36, at 139.
104 Andres Guadamuz Gonzalez, Open Science: Open 
Source Licenses in Scientific Research, 7(2) North 
Carolina Journal of Law & Technology, 321-366 (2006)
105 Janet E. Hope, Open Source Biotechnology 
(December 23, 2004) (unpublished Ph.D. dissertation, 
The Australian National University), 62, available at 
http://opensource.mit.edu/papers/hope.pdf.
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the owners or patentees who want to control 
access to these technologies on the other 
hand. Thus, in order to ensure that 
biotechnological research progresses 
effectively, what is needed is affordable and 
unfettered access to enabling technologies, 
all while protecting the interests of inventors.106 
Since the guiding principle of open models 
of technology transfer is unrestricted access 
to technology at a low cost, this article 
suggests that the targeted use of such 
models for the generation and transfer of 
biotechnological innovation may help pave 
the way to this objective. More importantly, 
there are also other benefits to using open 
approaches in biotechnology. Beyond having 
the potential of effectively addressing the 
perceived problems associated with the patent 
system, authors have discussed the numerous 
scientific, economic, and social advantages 
that are associated with the use of open 
approaches in biotechnology.107 
B) Practical Applications of Open and other 
Collaborative Models of Technology 
Transfer in Biotechnology
So-called “open” models have already 
begun to make their mark in the biotechnology 
industry. However, the reader should note 
that, to date, there do not seem to have been 
any specific attempts at defining what exactly 
constitutes an “open” project. The authors 
suggest that, similarly to open source, open 
models of collaboration are characterized by 
four basic features: freedom to access, copy, 
and modify information, and most importantly, 
106 Nicol, supra note 51, at 142.
107 See Joly, supra note 23, at 398-405. 
an obligation to publish downstream work 
under the same conditions (whether 
manifested through intellectual property 
rights or contracts). However, as will be seen, 
some existing biotechnological projects, 
although they do not incorporate copyleft-like 
restrictions, have nevertheless been 
characterized as “open” by the literature. 
These projects, although collaborative in 
certain respects, probably should not have 
been identified as such.
The authors believe that copyleft-like 
restrictions are critical to open models of 
collaboration even if it has been argued that 
such clauses are not necessarily needed to 
ensure that information remains freely 
available. One author suggests that putting 
certain research findings (such as the gene 
sequences that were mapped by the HGP) in 
the public domain “effectively excludes the 
patenting option until some additional step 
[is] taken”:108 since the research results are 
widely published, the invention does not 
sat isfy the novel ty  requirement  of 
patentability.109 Moreover, since information 
in the public domain is accessible to all, then 
there is also a good chance that inventions 
building upon this information could be 
obvious and thus again ineligible for 
patentability.110  However, the fact remains 
that the possibility of appropriating the work 
of upstream researchers, even if slight, still 
108 Nicol, supra note 51, at 148.
109 Gonzalez, supra note 104.
110 Jinseok Park, Evolution of Industry Knowledge 
in the Public Domain: Prior Art Searching for Software 
Patents, 2(1) SCRIPT-ed, 47 (2005), available at 
http://www.law.ed.ac.uk/ahrc/script-ed/vol2-1/park.asp 
(last visited June 30, 2007).
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exists.111 For example, in 1998, Craig Venter 
founded Celera Genomics, a private research 
lab with the goal of sequencing the human 
genome. One notes that the birth of this 
biotech company coincides in time with the 
HGP’s efforts to do the same. However, 
whereas the HGP’s goal was to make research 
findings publicly available on internet, 
Celera wanted to “[reap] the rewards of its 
investments”: it aimed to create a database 
that users could access, but only in exchange 
for a fee.112 Indeed, both projects were 
engaged in a veritable race to decode the 
genome because each tried to outdo the 
other’s attempt to privatise/publicize the data. 
For our purposes, what is important to note 
is that it has been suggested that Celera’s 
work “made extensive and inextricable use 
of the HGP genome information and thus 
[was] not an independent assembly of the 
human genome”.113 In other words, Celera 
could have, even if ultimately it was unable 
to, privatised the HGP’s openly published 
research findings for its own purposes.114 
Thus, this risk of unfair appropriation of 
information placed in the public domain 
111 Arti K. Rai & Rebecca Eisenberg, Harnessing 
and Sharing the Benefits of State-Sponsored Research: 
Intellectual Property Rights and Data Sharing in 
California’s Stem Cell Initiative (Duke Science, 
Technology & Innovation Paper No. 11), 21 Berkeley 
Technology Law Journal, 1207 (2006). 
112 RTD info: Magazine for European Research, 
Accelerating into a New Age, http://ec.europa.eu/
research/rtdinfo/en/27/genome01.html (last visited 
June 30, 2007). 
113 Robert H. Waterston, Eric S. Lander & John E. 
Sulston, More on the Sequencing of the Human Genome, 
100(6) Proceedings of the National Academy of Sciences 
of the United Stated of America, 3022-3024 (2003). 
114 Gonzalez, supra note 104. 
suggests that copyleft-like mechanisms are 
central elements of open models of 
collaboration in the field of biotechnological, 
and therefore stem cell, research.
It should also be noted that open models 
are but one specific subset of collaborative 
methods of technology transfer and since they 
have yet to be widely adopted in biotechnology, 
the following is an examination of other 
collaborative models of technology transfer 
and how they differentiate, or resemble, 
open models. 
Public Databases and/or the Public Domain
Putting information in the public domain 
means that anyone can access, use, and 
modify the information without permission 
and free of charge. It thus also follows that 
the information can be used for whatever 
purposes, proprietary or not.115 The public 
domain is more commonly considered to be 
a forum for materials that are, for whatever 
reason, ineligible for intellectual property 
protection; for instance, facts that lack the 
required level of originality for copyright 
protection and inventions whose patents have 
expired are placed in the public domain. 
However, it is possible to place copyrightable 
or patentable information in the public 
domain by renouncing to all intellectual 
property rights,116 such was the case for 
biotechnology projects such as the HGP. 
As previously discussed, there is a risk of 
private appropriation of information that was 
initially free. This situation is particularly 
115 University of California, UCCopyright, 
http://www.universityofcalifornia.edu/copyright/
publicdomain.html (last visisted June 30, 2007). 
116 Id. 
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worrisome in the context of stem cell 
research because of the capital intensive 
nature of R&D: self-interested downstream 
researchers could effectively rob upstream 
inventors of their considerable monetary 
investments by patenting an improvement 
of the foundational research results that were 
initially placed in the public domain. Thus, 
the public domain may not be ideally suited 
to harbour upstream information that costs 
a significant amount to generate, such as 
upstream stem cell inventions.
Patent Pools and Cross-Licensing 
A patent pool is “an agreement among 
patent owners to licence a set of their patents 
to one another or to a third party”:117 when 
multiple licences must be obtained in order 
to produce a final good, patent owners can 
come together and agree to cross-licence their 
patents to each other or licence them as 
“package” out to third parties.118 Such an 
arrangement would be desirable in a field of 
knowledge that develops cumulatively 
because, instead of having to negotiate 
licences and pay royalties for each added 
“layer” of innovation, the pooling of patents 
reduces the costs of technology transfer not 
only by streamlining or standardizing the 
negotiations process but also lessening the 
117 Josh Lerner & Jean Tirole , Efficient Patent Pools, 
94 American Economic Review, 691(2004); C. Shapiro, 
Navigating the Patent Thicket: Cross Licence, Patent 
Pools and Standard-Setting, in Innovation Policy and 
the Economy, Volume I (A. Jaffe, J. Lerner & S. Stern 
eds., MIT Press) (2001).
118 Patrick Gaulé, Towards Patent Pools in 
Biotechnology?, École polytechnique fédérale de 
Lausane, CDM Working Papers Serie, 2 (2006).
amount of licence fees to be paid.119 However, 
although patent holders benefit from these 
pools, consumers of the final product may 
be adversely affected if the participants of 
the patent pool collude and engage in 
anticompetitive practices so as to set the cost 
of the good unduly (and illegally) high. Past 
situations of antitrust put aside, patent pools 
have nevertheless been effectively used to 
commercialize many products.120
In the context of stem cell research, patent 
pools have been proposed as solutions to the 
alleged anticommons problem.121 However, 
the field of stem cell research is characterized 
by a few broad patents like WARF’s, rather 
than many concurrent patents, such that an 
anticommons is not necessarily a problem 
that has actually arisen. In any case, if these 
few patent holders were to form a patent pool, 
then only their research initiatives (or those 
of third parties who agree to pay for the 
“package” of licences) would benefit from 
the collaboration. But, when it comes to 
scientific progress in the field of stem cell 
research, many heads are probably better than 
just a few:122 according to Sornberger, “what’s 
119 Chris Dent, Paul Jensen, Sophie Waller & Beth 
Webster, A Research Use of Patented Knowledge: A 
Review, (OECD Directorate for Science, Technology 
and Industry) (2006). 
120 Jeanne Clark, Joe Piccolo, Brian Stanton & Karin 
Tyson, Patent Pools: A Solution to the Problem of Access 
in Biotechnology Patents?, (United States Patent and 
Trademark Office) (2000).
121 Goozner, supra note 30. 
122 The Steering Committee of the International Stem 
Cell Initiative, The International Stem Cell Initiative: 
Toward Benchmarks for Human Embryonic Stem Cell 
Research, 23(7) Nature Biotechnology, 796 (2005); Stem 
Cell Network, Catalyzing: Commercialization (August 
24, 2005), http://www.stemcellnetwork.ca/success/
commercial.php (last visited June 30, 2007).
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needed right now in stem cell biology is 
co-operation”.123 Therefore, to maximize 
innovation, as many scientists as possible 
should be brought into the picture, not just 
the few who are either members of the patent 
pool or wealthy enough to afford the license 
fees. Moreover, patent pools, in and of 
themselves, lack copyleft-like mechanisms. 
Hence, theoretically, improvements to 
upstream information could be patented and 
subsequently withheld from the pool. Should 
this be the case, we would still be faced with 
the potential patent-related problems of 
hampering research.124 In light of the two 
research impediments presented above, 
patent pools might not be ideal models for 
the transfer of stem cell technologies
Clearinghouse Mechanisms
A clearinghouse is described as a system 
that simplifies the process of finding and 
negotiating licences by providing a platform 
for matching providers and users of patented 
inventions, based on a number of different 
criteria.125 Potential licensees can pick and 
choose from a clearinghouse those patents 
which are most relevant for their purposes. 
Moreover, “a clearinghouse could perform 
one or more of the following functions: 
facilitating the search for technology that is 
123 Joe Sornberger, Critical Mass, 5(1) Stem Cell 
Network, 7 (2006). 
124 See section 2B on “Patenting Key Upstream 
Inventions” and “Patent Scope”.
125 Esther van Zimmeren, Birgit Verbeure, Gert 
Matthijs & Geertrui Van Overwalle, A Clearing House 
for Diagnostic Testing: The Solution to Ensure Access to 
and Use of Patented Genetic Inventions?, 84(5) Bulletin 
of the World Health Organization, 352 (2006). 
available for licensing or free use; smoothing 
the progress of negotiations; and monitoring 
or enforcing negotiated agreements.”126 
Clearinghouses have been proposed as 
mechanisms that could alleviate the possible 
research impediments associated with the 
presence of concurrent patents in the field of 
stem cell research (i.e. an anticommons): 
since clearinghouses allow researchers to 
navigate the “thicket” with relative ease, the 
risk of the development of an anticommons 
is diminished.127 However, we have established 
that an anticommons is not a serious threat 
to the timely progression of stem cell research 
because such a situation presupposes the 
existence of many fragmented and concurrent 
patents whereas this field of knowledge is, in 
reality, characterized by a few broad patents. 
Thus, that clearinghouses have the potential 
for remedying an anticommons, would not 
justify their use in the context of stem 
cell research.  
It is also argued that the creation of 
clearinghouses can lead to an overly strict 
enforcement of intellectual property rights, 
including rights that are of uncertain validity, 
and thereby hinder downstream research 
efforts.128 For example, the validity of the 
American WARF patents has yet to be 
unequivocally determined. If a clearinghouse 
grouping hESC related patents were to be 
created, the WARF patents would undoubtedly 
be listed in it. But, the fact that the patents 
are listed would also suggest that they 
are valid; by consequence, a downstream 
126 Nicol, supra note 51, at 145. 
127 Karl & Graff, supra note 73, at 422. 
128 Nicol, supra note 51, at 145. 
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inventor could be deterred from engaging in 
any further research because of the expected 
transaction costs associated with negotiating 
a licence. In other words, clearinghouses 
could restrict the timely development of a 
field of knowledge because, by assuming the 
validity of the patents they inventory, they 
can mislead downstream inventors into 
wanting to avoid the licensing headaches 
that presumably accompany a validly 
patented invention. 
Open models, the public domain, patent 
pools, and clearinghouses all present 
advantages and disadvantages regarding their 
ability to assist in, or conversely their 
potential to hinder, the advancement of 
stem cell research. However, of all these 
collaborative models, open models seem most 
suited to the aforementioned goal because of 
their unparalleled ability to spread and 
generate high-quality information, quickly, 
all while protecting it from being unfairly 
appropriated by downstream users. 
Indeed, in light of this research field’s 
relatively early stage of development, open 
models seem to be especially appropriate. 
Under a traditional proprietary regime, due 
to licensing complexities and potential 
resistance to collaboration among scientists 
(in order to maintain novelty in would-be 
patent applications)129, it could take decades 
before basic stem cell research can be 
developed into something clinically useful. 
In addition, with respect to industry, currently, 
investing in biotechnological R&D is quite 
risky due to the high levels of capital required 
129 Yann Joly, Flora Wahnon & Bartha M. Knoppers, 
Impact of Commercialization in Biotechnology Research: 
North American Perspective, 8:1 Harvard Health Policy 
Review, 71.
and the low chances of successfully producing 
a marketable product.130 But, open models 
diffuse the risk among many contributors, 
thus allowing for further investment into 
biotechnological research, and thereby 
increasing the significance of the other 
benefits linked to open models of technology 
transfer. Hence, in stem cell research, whether 
one considers their ability to maintain the 
pace of research development or the benefits 
they confer to the corporate community, open 
modes of technology transfer may, in certain 
circumstances, be preferable to classic 
proprietary schemes for the management 
of intellectual innovation. Indeed, the 
biotechnological research sector has begun 
to recognize the benefits of collaborative 
models: the following biotechnology 
projects, although not purely open models, 
have all successfully incorporated certain 
elements of open models to achieve their 
research goals. 
The Human Genome Project (HGP)
The HGP was launched to, among other 
objectives, identify all the genes in human 
DNA. It spanned thirteen years from 1995 to 
2003 and was administered by the US 
Department of Energy and the National 
Institutes of Health. Since the completion of 
the mapping in 2003, several “in-depth 
analyses of complete chromosomes” have 
been published. 131 
130 Resnik, supra note 25, at 130; Basheer, supra 
note 25. 
131 The Human Genome Program of US Department 
of Energy Office of Science, Human Genome Project 
Information, http://www.ornl.gov/sci/techresources/
Human_Genome/home.shtml (last visited June 
30, 2007).
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The HGP was an international endeavour 
lead by five major sequencing centers: the 
Sanger Institute, the Washington University 
Genome Sequencing Center, the Whitehead 
Institute, the Baylor College of Medicine, and 
the Joint Genome Institute.132 The participants 
did not patent their findings and instead 
shared them by placing the information in the 
public domain.133 The success of the HGP has 
often been attributed to the collaborative 
spirit of the participants.134
The International Haplotype Mapping 
Project (HapMap)
HapMap describes itself as a “partnership” 
between Canada, China, Japan, Nigeria, the 
United Kingdom, and the US with the goal 
132 Wellcome Trust Sanger Institute, Historic 
Overview of the HGP up to 2003, http://www.sanger.
ac.uk/HGP/overview.shtml (last visited June 30, 2007). 
133 Rai, supra note 36, at 142; Human Genome 
Research Institute, National Institutes of Health, 
Department of Health and Human Services, Office of 
Science US Department of Energy, Human Genome 
Project Information: Genetics and Patenting, http://www.
ornl.gov/sci/techresources/Human_Genome/elsi/patents.
shtml#7 (last visited June 30, 2007).
134 For example: F. Collins & D. Galas, A New Five-
Year Plan for the US Human Genome Project, 262 
Science, 43-46 (1993); U.S. Department of Energy 
Office of Science, Office of Biological and Environmental 
Research, Human Genome Program, Human Genome 
Project Information: Revised 5-Year Research Goals of 
the U.S. Human Genome Project, http://www.ornl.gov/
sci/techresources/Human_Genome/project/5yrplan/
5yrplanrev.shtml (last visited June 30, 2007); National 
Human Genome Research Institute, National Institutes 
of Health, Department of Health and Human Services, 
Office of Science US Department of Energy, International 
Consortium Completes Human Genome Project: All 
Goals Achieved; New Vision for Genome Research 
Unveiled, http://genome.gov/11006929 (last visited 
June 30 2007). 
of uncovering associations between specific 
diseases, genes, pharmaceutical products, and 
environmental factors.135 The project was 
launched in 2002 and completed in 2005 
when a “comprehensive catalogue of human 
genetic variation” outlined the most common 
differences in the human genome.136 This 
effort has been heralded as a catalyst for 
personalized disease treatment because the 
identification of the different variations will 
reduce the cost of carrying out research into 
the genetic causes of disease.137
All the information generated was released 
into the public domain.138 However, similarly 
to the copyleft principle, HapMap also 
implemented a click-wrap licence whereby 
anyone who accessed and used the data in 
their own work had to first agree (1) not to 
restrict the access of others and (2) not to 
patent the work.139 Interestingly, in December 
2004, the International HapMap Consortium 
decided that enough raw data had been 
produced to justify the removal of the click-
wrap and thereby permit unrestricted access 
135 International HapMap Project, International 
HapMap Project, http://www.hapmap.org/index.html.en 
(last visited June 30, 2007). 
136 Massachussetts Institute of Technology, HapMap 
Provides ‘Catalog’ of Human Genetic Variation (October 
27, 2005), http://web.mit.edu/newsoffice/2005/hapmap.
html (last visited June 30, 2007).
137 BBC News, Gene Map Points to Personal Drugs 
(26 October 2005), http://news.bbc.co.uk/1/hi/
health/4378624.stm (last visited June 30, 2007). 
138 International HapMap Projectm International 
HapMap Project: Home, http://www.hapmap.org/index.
html.en (last visited June 30, 2007).
139 Herder, supra note 21, at 35; Rai, supra note 36, 
at 142-143; Mulgan, Steinberg & Salem, supra note 87, 
at 61.
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to research results.140 Much like the HGP, 
HapMap has been hailed as landmark project 
in medicine and commended for its use of 
collaborative methods.141
The Biological Innovation for Open 
Society (BIOS)
The BIOS initiative is aimed at developing 
innovation systems for disadvantaged 
communities and neglected priorities. It is 
funded by CAMBIA, an international, non-
profit research institute with the same goals 
as its subsidiary BIOS. 
To attain its goal, BIOS will produce and 
publish research with respect to three types 
of biotechnological research tools in a 
“protected, universally-accessible commons”: 
the Patent Lens is a database to archive 
patents; the BioForge is a platform to support 
the open communication of innovation; 
and the Bios Foundation will consider 
the successes achieved, or the obstacles 
encountered, to create a model framework for 
the “democratization” of innovation. 142 
140 Wellcome Trust Sanger Institute, International 
HapMap Consortium Releases All Data to the Public: 
HapMap Will Help Identify Genetic Contributions to 
Disease (August 2, 2007) http://www.sanger.ac.uk/Info/
Press/2004/041213.shtml?;decor=printable (last visited 
September 30, 2007).
141 For example: Bartha M. Knoppers & Yann Joly, 
Our Social Genome?, 25(7) Trends in Biotechnology, 
284-288 (2007); Wellcome Trust, International 
Consortium Completes Map of Human Genetic 
Var ia t ion ,  h t tp : / /www.wel lcome.ac .uk/doc_
WTX027367.html (last visited June 30, 2007).
142 The CAMBIA BIOS Initiative: Biological 
Innovation for Open Society, Implementation Phase 
2006-2008, (The CAMBIA BIOS Initiative) (2006), 
available at http://www.bios.net/daisy/bios/2029/
version/default/part/AttachmentData/data/BiOS%20
Initiative%20Phase%202006-2008.pdf. 
The Bioforge is managed in a copyleft-
like spirit:143 those who wish to participate in 
the project agree that generated data can be 
patented provided that “improvements are 
shared, and that licensees cannot appropriate 
the fundamental ‘kernel’ of the technology 
and improvements  exclus ive ly  for 
themselves”.144 The BioForge currently has 
twelve ongoing projects, in a variety of 
different subjects.145 
6. OPEN MODELS IN STEM CELL 
RESEARCH
A) Potential Obstacles to the Implementation 
of Open Models in Biotechnological and 
Stem Cell Research
The software writing context is very 
different from the stem cell research context, 
and as such, it is important to discuss in what 
ways the two fields of knowledge differ in 
order to determine whether the open source 
method could be successfully adapted to stem 
cell research. 
Nature of Research Tools
In computing, raw materials are intangible 
data contained in the source codes whereas 
in biotechnology, research materials are often 
tangible objects such as embryos or stem 
143 Gonzalez, supra note 104.
144 CAMBIA, About BIOS (Biological Open Source) 
Licenses, http://www.bios.net/daisy/bios/398 (last 
visited June 30, 2007); Mulgan, Steinberg & Salem, 
supra note 87, at 60.
145 BioForge: Biological Innovation, BioForge: An 
Online Community for Biological Innovation, http://
www.bioforge.net/forge/kbcategory.jspa?categoryID=2 
(last visited June 30, 2007).
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cells. With respect to the adoption of open 
models in the field of stem cell research, the 
problems that may eventuate due to this 
discrepancy are significant. 
First of all, while source codes can be 
protected by, among other forms of protection, 
copyright, biotechnological inventions are 
most often protected by patent. Copyrights 
can be obtained and maintained free of charge 
or very cheaply, patents are expensive legal 
tools. For example, it has been said that in 
the US, a patent application can cost 7,500 
USD and defending a patent can cost up to 
1.6 million USD.146 These discrepancies in 
costs with respect to obtaining and maintaining 
protection of the research tools in computing 
on the one hand, and in biotechnology on the 
other hand, means that patent owners may be 
more reticent to the idea of giving open access 
to their inventions than source codes 
developers are.147 It has also been noted 
that, as compared to copylefts that deal with 
copyrightable material, the corresponding 
copyleft-like licences for patentable materials 
can be extremely complex due to the nature 
of the innovation in question; for instance, 
the BIOS open licence, although still a work in 
progress, is described by one observer as being 
riddled with ambiguity and technicalities.148 
Confusing and complex licences could 
discourage researchers from adopting open 
methods of technology transfer.
Secondly, it is noted that software data is 
“modular and compartmentalised” such that 
it is easier to make improvements to certain 
146 Gonzalez, supra note 104; Joly, supra note 23, 
at 388.
147 Nicol, supra note 51, at 147.
148 Gonzalez, supra note 104.
parts of the program with only minimal and/
or foreseeable repercussions on the rest of the 
program. In contrast, making modifications 
to biotech “hardware” can have unpredictable 
effects. 149 Moreover, since biotech research 
tools are not modular and compartmentalised, 
subsequent researchers may not be able to 
rely on previous output without some sort of 
standardization of the data.150 
Third, the development and production 
of hardware in the field of biotechnology is 
much more capital intensive than for software. 
The amount of financial commitment to 
bring a biotechnological stem cell project to 
term is substantial whereas start-up and 
development outlays for software development 
are minimal.151 Due to this difference in 
capital costs, it is said that biotechnology 
researchers would be less inclined to adopt 
open attitudes with respect to access to their 
work.152 However, in response to this 
argument, scholars submit that the emphasis 
on the glaring difference in costs in the 
computing field versus the biotechnology 
field is exaggerated; it is argued that with 
contemporary advances in technology, the 
cost of doing wet lab or biotechnological 
research is rapidly decreasing such that the 
reluctance to adopt an open model in biotech 
cannot be entirely justified based on the 
capital costs of research.153
149 Janet Hope, Open Source Biotechnology?, http://
rrss.anu.edu.au/~janeth/OSBiotech.html (last visited 
June 30, 2007).
150 Rai, supra note 36, at 149.
151 Mulgan, Steinberg & Salem, supra note 87, at 
17; Nicol, supra note 51, at 147.
152 Rai, supra note 36, at 148ff; Hope, supra 
note 149. 
153 Hope, supra note 149.
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Effects of Open Biotechnology on Public 
Health and Safety 
Unlike with software, biotechnology 
researchers must abide by biosafety and 
biosecurity regulations having to do with, for 
instance food, drugs, tissue, or the isolation 
of stem cells. It has been argued that these 
regulated obligations may complicate the task 
of doing collaborative biotechnological 
research and consequently diminish the 
appeal of open models. A counter-argument 
is that software developers must comply with 
export laws and this has not stopped them 
from open sourcing programs.154 
Thus, what is perhaps at the root of this 
issue is that, with respect to biotechnological 
research and unlike open sourced software, 
there is a fear that permitting open access to 
biotech innovations may pose threats to 
public health.155 For example, if anyone can 
access the recipe for a very powerful drug or 
uncover the process for cloning human 
beings, then the careless or malevolent 
handling of this information could potentially 
put an uninformed population at risk. Of 
course, it is also said that no matter how much 
sensitive biotech information is protected, 
individuals with enough bad intent will find 
a way to access it. In any case, since in open 
biotechnological research the public’s health 
and safety seem to be more vulnerable than 
in open source computing, it is argued that 
open models of collaboration may be less 
suitable for the former field.
154 Id. 
155 Id. 
Lack of Infrastructure to Support 
Open Models of Collaboration in 
Biotechnology
Another issue that computer software 
developers need not concern themselves with 
is infrastructure. Although the copyleft 
concept has been institutionalized in the open 
source software context (for example, the 
GPL), these types of legal mechanisms are 
not yet fully developed in biomedical 
research.156 Although some open initiatives 
such as HapMap and BIOS have made use of 
copyleft-like principles to prevent the 
appropriation and patenting of public 
information, there is still a need for a more 
robust framework to ensure the viability of 
open models in biotechnological research. 
The Importance of “Being Published”
In open sourced computing, innovation is 
uniformly disseminated through the public 
disclosure of source codes. Thus, the choice 
of “channel” of publication of information is 
a non-issue. Conversely, in the field of 
biotechnology, research results that are 
published in scientific journals or reviews are 
regarded with higher esteem than information 
that is informally published via, for instance, 
the internet. However, the problem lies in the 
fact that scientific journals or reviews may 
be reluctant to publish studies that rely on 
data that have already been informally 
disseminated: 157  if journals refuse to publish 
research based on openly disseminated 
156 Yochai Benkler, The Wealth of Networks: How 
Social Production Transforms Markets and Freedom, 
Chapter 9, (Yale University Press) (2006).
157 Rai, supra note 36, at 144. 
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information, then such research, albeit 
valuable, may be ignored by the scientific 
community thereby defeating the purpose 
of using open approaches (i.e. to help 
research progress). However, since journals 
are likely to be sensitive to the need for open 
models of technology transfer, the right 
amount of pressure from researchers could 
convince them to publish work that has 
already been disseminated. 
Conflicts of Interests between Technology 
Transfer Offices (TTOs) and Biotechnology 
Researchers
A final difference between software 
writing and biotechnology that may prevent 
the successful implementation of open 
models is the presence of conflicts of interests 
between TTOs and biotechnology researchers. 
TTOs are responsible for transferring 
intellectual property between universities, 
companies, and other organizations. These 
offices will often want to enforce intellectual 
property rights to maximize revenues from 
patent licence royalties.158 This may conflict 
with scientists’ interests in obtaining income 
from consulting fees.159 In other words, if 
individual biotechnology researchers receive 
revenue by sharing their expertise with other 
users of the technology in question, then 
they will want to adopt an open model of 
collaboration to maximize their potential 
number of clients. However, this may clash 
with the university’s/company’s/organization’s 
158 Matthew Herder & Jennifer Dyck Brian, 
Canada’s Stem Cell Corporation: Aggregate Concerns 
and the Question of Public Trust, 77(1) Journal of 
Business Ethics, 73-84 (2007).
159 Rai, supra note 36, at 146.
interest in obtaining royalties, in which case 
proprietary frameworks will be favoured. 
Should these two parties fail to agree on a 
primary goal, this conflict of interests could 
prevent the effective implementation of open 
models of collaboration in the context of 
biotechnological research.
The differences that exist between open 
source computing versus open biotechnology 
may complicate the adoption of open 
approaches in stem cell research.  Moreover, 
to date, such models do not seem to have 
been widely used in the field of stem cell 
research such that it is difficult to assess their 
applicability and effectiveness. However, 
despite these uncertainties, some believe that 
the patent-related access to technology 
problems could be successfully resolved by 
open approaches of technology transfer due 
to their emphasis on “commons-based 
strategies”.160 The authors also suggest 
considering the use of open models of 
collaboration based on the benefits that they 
can bring to the field of stem cell research. 
Indeed, in addition to the benefits of open 
approaches enumerated previously, there are 
further advantages that would flow from the 
adoption of open approaches in the stem cell 
research environment. 
B) Benefits of Open Models in Stem Cell 
Research
Economic Benefits
The literature has identified six main 
economic benefits of using open models in 
stem cell research. First, it could help lower 
160 Herder, supra note 21. 
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the costs of technology transfer. Since R&D 
outlays are diminished and since research 
does not necessarily need to be patented, the 
costs of transferring technologies from one 
researcher to another can be much lower. 
Second, the open dissemination of projects 
will allow individual researchers to be more 
quickly and easily aware of what information 
has already been made available. Thus, 
scientists will know not to duplicate research 
on issues that have already been explored by 
others. Third, there may be a development of 
a market for complementary goods and 
services. By openly publishing stem cell 
research results, companies could bolster the 
marketability of their complementary 
proprietary goods.161 Fourth, the use of open 
models could improve a company’s reputation. 
Allowing fellow scientists free access to 
research results could strengthen a company’s 
social and technical reputation162 in turn 
increasing its overall appeal to consumers. 
Fifth, since the research burden is spread 
out among a group of contributors, open 
approaches have the ability to keep R&D 
costs low.163 It should be noted that R&D 
outlays also include the costs of taking the 
risk of investing in expensive and potentially 
unprofitable projects. Sixth, open source 
could eliminate or significantly diminish the 
need for negotiations. It has been argued that 
patents slow the transfer of technology 
161 Janet E. Hope, A New Way to Manage Scientific 
Intellectual Property, 18(1) GeneWatch Magazine, (2005), 
available at http://www.gene-watch.org/genewatch/
articles/18-1Hope.html (last visited June 30, 2007). 
162 Hope, id.
163 Rai, supra note 36, at 138; Mulgan, Mulgan, 
Steinberg & Salem, supra note 87, at 16ff. 
partly because obtaining licences involves 
negotiation.164 In open models, since there are 
often no patents, obtaining necessary upstream 
information does not require any time-
consuming negotiations.165
Social Benefits
The social reasons for adopting open 
models of technology transfer are also 
compel l ing.  Since open models  of 
collaboration allow researchers to view and 
vet each other’s work more quickly and 
accurately, individual scientists may earn 
greater respect for their work from their peers 
because many people will have had the 
opportunity to appraise its quality.166 
Moreover, since open projects allow everyone 
to view each other’s work, participants may 
feel encouraged to work harder in order to 
gain recognition from their target audience 
(i.e., peers, the labour market, venture capital 
communities).167 Finally, open models could 
assist in promoting healthcare in developing 
countries; because the research burden is 
spread out among a group of contributors, 
open approaches have the ability to keep 
R&D costs low.168 This being said, open 
models of collaboration that encourage the 
participation of developing countries will 
164 Constance Holden, US Patent Office Casts Doubt 
on Wisconsin Stem Cell Patents, 316(5822) Science, 
182 (2007).
165 Hope, supra note 105, at 99.
166 Josh Lerner & Jean Tirole, The Economics of 
Technology Sharing: Open Source and Beyond, 19 
Journal of Economic Perspectives, 104 (2005). 
167 Joly, supra note 23, at 402-404.
168 Rai, supra note 36, at 138; Mulgan, Steinberg & 
Salem, supra note 87, at page 16ff.
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allow these countries to build upon their own 
medical research at a low cost.169 
7. CASE STUDIES OF 
CONTEMPORARY 
COLLABORATIVE MODELS 
IN STEM CELL RESEARCH
This analysis will seek to gather empirical 
evidence on the successes and failures of 
collaborative projects in order to gauge the 
extent to which the introduction of open 
models would be beneficial to this field. 
A) Aggregate Therapeutics Inc. (ATI) 
(originally called StemNetCo)
Year of Creation: 2005
Current  S tage  o f  Deve lopment : 
Operational
Type of Funding: Formally public funding, 
now a mix of public and private funding
General Description: ATI used to be 
the Stem Cell  Network’s for-profit 
commercialization arm. The Stem Cell 
Network is part of Canada’s Networks of 
Centres of Excellence, collaborative science 
and technology research enterprise. The Stem 
Cell Network has recently partnered with the 
MaRS Discovery District170, a non-profit 
networking corporation whose mission is to 
encourage collaboration between the science, 
business, and capital communities. The Stem 
Cell Network has in effect relinquished 
169 For example: Maurer, Rai & Sali, Finding Cures 
for Tropical Diseases: Is Open Source an Answer?, 1(3) 
PLoS Medicine December, e56 (2004).
170 MaRS, About MaRS (2007), http://www.marsdd.
com/About-MaRS.html (last visited September 
30, 2007).
control of ATI to MaRS who now ensures its 
continued funding and management.171
AT I  h o l d s  e x c l u s i v e  f i r s t 
commercialization rights to development-
stage stem cell therapies from thirty-seven 
Canadian scientists at sixteen universities 
and research centres in exchange for making 
these contributors company shareholders. 
The company then streamlines the process of 
developing stem cell therapies by “aggregating 
complementary technologies and leveraging 
them across a common development platform, 
management team and source of capital.”172 
Finally, it licences these bundles of rights 
out to industry. All technologies remain 
available for research purposes by scientists 
of the Network.173 
Method of Technology Transfer: ATI is 
an intermediary between researchers, their 
institutions, and the market place. It contributes 
to the relationship by adding commercialisation 
171 MaRS Discovery District, New Partnership 
Leverages Promising Canadian Stem Cell IP: MaRS and 
Canadian Stem Cell Network Partners in Transnational 
Development Company Focused in High Growth Area 
of Regenerative Medicine (April 11, 2007), http://www.
marsdd.com/News/Press-Releases/2007/Stem-Cell-
Partnership20070411.html April 11 2007 (last visited 
September 30, 2007).
172 Id. 
173 Networks of Centres of Excellence Canada, Stem 
Cell Network: NCE Spin Off Company Partners with 
Investigators and Universities to Bring Regenerative 
Medicine to Market (December 7 2006), http://www.
nce.gc.ca/pubs/ncenet-telerce/dec2006/scn-dec06_e.htm 
(last visited September 30, 2007); Stem Cell Network, 
Catalyzing: Commercialization (August 25 2005), http://
www.stemcellnetwork.ca/success/commercial.php (last 
visited September 30, 2007); MaRS Discovery District, 
Stem Cell Network Teaming with MaRs to Accelerate 
Commercialization Efforts, 21(7) Research Money, 3 
(2007); Aggregate Therapeutics Inc. License Agreement 
Template (Aggregate Therapeutics Inc.: Ottawa, 
2005-2007). 
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expertise and by helping to leverage and 
aggregate promising technologies. In certain 
respects, ATI is similar to a patent pool: 
ATI collaborators bundle their patents and 
agree to let other members of industry use 
and improve upon their bundled technologies 
in consideration for a percentage of the 
licensing fees. 
Benefits Provided to the Scientific 
Community and the Public at Large: To date, 
the Networks for Centres of Excellence and 
ATI account that the project has identified 
over sixty-five new technologies174 based on 
stem cells from the skin, pancreas, retina, and 
bone marrow and has optioned or licensed 
out eight of them. The ATI team reports that 
two of these discoveries in particular, namely 
skin-derived precursor cells and new 
treatments for diabetes, are “breakthroughs”.175 
Moreover, it is looking to secure between ten 
and twenty million USD to finance further 
commercialization efforts and expects to 
launch its first regenerative medicine product 
within five years.176 
Finally, ATI is also playing an important 
role in supporting the members of the 
scientific community in their endeavours by 
informing them of the different aspects of 
the commercialisation process and by 
174 Aggregate Therapeutics Inc., Portfolio (2007) 
http://www.aggregatetx.com/ (last visited September 
30, 2007).
175 Aggregate Therapeutics Inc. ,  Featured 
Technologies (2007) http://www.aggregatetx.com/ 
(last visited September 30, 2007). 
176 Networks of Centres of Excellence Canada, Stem 
Cell Network: NCE Spin Off Company Partners with 
Investigators and Universities to Bring Regenerative 
Medicine to Market (December 7, 2006), http://www.
nce.gc.ca/pubs/ncenet-telerce/dec2006/scn-dec06_e.htm 
(last visited September 30, 2007). 
lending expertise to university technology 
transfer offices.
However, as vibrant as the company 
seems, others are not convinced of the 
benefits of this new technology transfer 
model. Herder and Brian contend that ATI’s 
commercialization activities are problematic 
because they benefit the company’s 
shareholders, i.e. the contributing researchers, 
but at the expense of its stakeholders, the 
Canadian public that expects to benefit from 
new stem cell therapies. Herder and Brian 
explain that this “breach of public trust” 
occurs for three reasons: first, conflicts of 
interests may arise because whereas the 
public is anticipating great medical benefits 
for society at large, ATI only has an interest 
in developing the technologies that will 
generate the most income; these interests will 
obviously not always necessarily coincide. 
Secondly, and as a consequence of the first 
point, a breach of public trust may arise 
because of the corporate-driven nature of 
research. Since ATI’s research efforts will be 
spurred by the financing of corporate venture 
financiers, the technologies produced with 
these patented tools will only be those that 
can recoup high profits. In other words, the 
products developed using technologies 
licensed from ATI might not be amenable to 
distribution in a publicly-funded healthcare 
system, the system that most citizens depend 
on for care. Thirdly, it is contended that the 
taxpayer will be forced to pay twice for the 
same end-product; once to fund the research 
and again to obtain the actual technology. In 
short, according to Herder and Brian, the 
combination of these three issues could result 
in a perception that ATI is breaching the 
Canadian public’s trust.177 
177 Herder & Brian, supra note 158. 
Revista da Faculdade de Direito - UFPR, Curitiba, n.47, p.101-139, 2008.
133
However, this negative review of ATI has 
been contested. Indeed, one author contends 
that government funded initiatives do not 
normally guarantee “a specific return on that 
public investment”; thus, expecting ATI to 
produce stem cell therapies to benefit the 
entire Canadian public is unreasonable.178 
This debate illustrates the difficulty of 
promoting commercially sustainable models 
of stem cell technology development all while 
avoiding the ethical pitfalls attributed to 
research commercialisation. However, with 
respect to public institutions involved in 
fundamental stem cell research, ATI’s system 
of technology transfer is nevertheless a model 
worth exploring and perfecting.
B) The International Stem Cell Forum 
(ISCF) and the International Stem 
Cell Initiative
Year of Creation: 2003
Current  S tage  o f  Development: 
Operational
Type of Funding: Mix of public and 
private international organizations 
General Description:  The United 
Kingdom ISCF consists of fourteen funding 
organizations that are committed to the 
advancement of stem cell research through 
collaboration and funding support. Since its 
inception, the ISCF has launched four major 
projects to address key issues: (1) the 
standardisation of criteria for characterisation 
(i.e. identification) of stem cell lines; (2) an 
178 Chris Macdonald, The Business Ethics Blog: 
Aggregate Therapeutics and profit for Publicly Funded 
Research (March 1 2007), http://www.businessethics.
ca/blog/2007/03/aggregate-therapeutics-and-profit-
from.html (last visited September 30, 2007). 
analysis of the different national ethical 
policies relating to stem cell research; (3) an 
analysis of the different national intellectual 
property regimes; and (4) the development 
of the ISCF website to facilitate the diffusion 
of information on stem cell research.179 The 
parameters of research objective (1), otherwise 
known as the International Stem Cell 
Initiative, seem most akin to a collaborative 
model of technology transfer because, unlike 
the other three projects, the characterisation 
project involves scientists from six different 
countries contributing research results in 
order to draw up globally agreed criteria for 
characterising stem cell lines
Method of Technology Transfer: All the 
information produced by the project will be 
made publicly available on the ISCF internet 
registry.180 One of the other Initiative’s 
leaders has stated that “our central aims are 
to provide openness and reliability; and to 
enable scientists to reproduce and extend each 
other’s work.” 181 Indeed, the Initiative has 
already “established a comprehensive registry 
of cell lines and their molecular characteristics 
which is soon to be made freely available 
to the wider scientific community.”182 
In other words, it seems that the Initiative 
179 International Stem Cell Forum, Forum Initiatives 
(2007), http://www.stemcellforum.org.uk/about_the_
iscf/forum_initiatives.cfm (last visited September 
30, 2007). 
180 International Stem Cell Forum, Project Overview 
(2007), http://www.stemcellforum.org.uk/registries_&_
banks/characterising_cell_lines/project_overview.cfm 
(last visited September 30, 2007). 
181 Medical Research Council, Agreeing What 
Makes a Stem Cell (February 3, 2007), http://www.mrc.
ac.uk/NewsViewsAndEvents/News/MRC003489 (last 
visited September 30, 2007).
182 Id.
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will rely on the public domain to disseminate 
its findings. 
Benefits Provided to the Scientific 
Community and the Public at Large: The 
ISCF reports that the Initiative has already 
completed phase one of five phases in the 
characterisation project: (1) UK Stem Cell 
Bank acquires and prepares antibodies for 
distribution to participating laboratories; (2) 
Recruitment of participant laboratories; (3) 
Experimental work; (4) Analysis of results; 
(5) ISCF workshop to discuss results and 
reach consensus on conclusions, followed by 
publication on ISCF online registry. Moreover, 
according to the ISCF’s chair, funding 
organizations are continually joining the 
Forum in a concerted effort to advance stem 
cell research.183 
However, the fact that this project uses 
the public domain to transfer its technology 
can be problematic because of the risk of the 
appropriation of upstream work by a 
downstream scientist. The concern is that, 
with publicly available databases, 
commercial providers would find large 
sections of readily available information that 
can be repackaged and resold as part of a 
commercial database. [Release of information 
into the public domain] is extremely useful 
for future researchers, but it does little to curb 
the further commercialization of the data.184
In other words, the downstream user 
looking to make financial gain from this 
freely available information need only make 
an improvement of any type to the data, and 
then impose restrictions on the entire block 
183 Id. 
184 Gonzalez, supra note 104, at 324. 
of information by way of contractual clauses 
(or a sui generis right in Europe); anyone 
viewing this new database must agree not to 
copy the information for their own purposes. 
However, if the use of the improvement is 
crucial for further research, these clauses 
could potentially halt the chain of progress. 
Therefore, the use of the public domain may 
not be the best vehicle for the dissemination 
of ISCF’s because profiteering individuals 
could slow the Initiative’s progress in identifying 
universal criteria for the characterisation of 
stem cell lines.
C) The WiCell Research Institute and the 
National Stem Cell Bank
Date of Creation: 2005
Current  S tage  o f  Development: 
Operational
Type of Funding: Federally funded
General Description: The US WiCell 
Research Institute is a subsidiary of the 
WARF and is committed to studying the 
scientific and medicinal potential of stem 
cells. In 2005, the National Institutes of 
Health (the primary federal agency for 
conducting and supporting medical research 
in the US) awarded the Institute the “National 
Stem Cell Bank” contract which made it the 
country’s only repository for hESC that are 
listed on the NIH’s Registry and therefore 
eligible for federal funding. The patent 
holders of these stem cell lines are located all 
over the globe but the National Stem Cell 
Bank inventories thirteen of the twenty-one 
hESC lines eligible for federal funding in 
the US.185 
185 Jill Ladwig, A Scientific Treasure for the Future, 
WiCell Journal of Stem Cell Discovery, 7-11 (Winter 
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The National Stem Cell Bank’s mandate 
is to: 
acquire, characterize and distribute the 21 cell 
lines on the NIH Registry, and to provide 
technical support to researchers who work 
with the cells at academic and non-profit 
institutions. […The goal is], with the agreement 
of the cell owners, to maintain, produce and 
distribute these lines to the research 
community.186
To do so, the Bank aggregates the cell 
lines, performs sophisticated characterization 
research on them, and subsequently 
standardizes the results for further use by 
other scientists.187
Method of Technology Transfer: The 
National Stem Cell Bank incorporates the 
characteristics of a clearinghouse. Among 
other roles, it catalogues stem cell lines in 
view of simplifying the process of finding 
and negotiating stem cell licences. By 
consolidating the majority of hESC lines that 
are eligible for federal funding and by 
standardizing characterization protocols, the 
Bank is effectively performing the functions 
of a clearinghouse for academic or non-profit 
inventors seeking to perform downstream 
stem cell research. 
Benefits Provided to the Scientific 
Community and the Public at Large: In 
fulfilling its mandate, the Bank has been 
commended for lowering the transaction 
costs associated with, and thereby facilitating 
2006), available at http://www.wicell.org/index.
php?option=com_content&task=category&sectionid=7&
id=233&Itemid=240; University of Wisconsin-Madison, 
National Stem Cell Bank Announces Addition of New 
Cell Lines (September 19, 2006), http://www.news.wisc.
edu/12890 (last visited September 30, 2007). 
186 Ladwig, supra note 185. 
187 Id.
the process of, transferring stem cells to 
scientists.188 Moreover, in February 2007, the 
Bank teamed up with the U.K. Stem Cell Bank 
to maximize efforts in creating international 
standards for the isolation of hESC and in 
distributing the stem cell lines.189 
D) Possible Applications of Open Models 
in Stem Cell Research
These case studies are a tribute to the 
relative success of collaborative models of 
technology transfer in the field of stem cell 
research. To be sure, several issues must be 
addressed in order to maximize progress in 
each of the aforementioned projects. But, given 
the current successes of these endeavours, it 
nevertheless seems that both the scientific 
and lay communities would be receptive to 
the introduction of another technology 
transfer model that is perhaps the most 
collaborative of them all, the open model.
That is not to say that open models should 
completely replace intellectual property 
rights in stem cell research. On the contrary, 
property rights should still have an important 
role to play. However, these traditional 
proprietary schemes ought to be reconsidered 
from a collaborative point of view so that 
each project’s respective goals may be 
effectively achieved all while maintaining the 
188 National Institutes of Health, NIH Awards a 
National Stem Cell Bank and New Centers of Excellence 
in Translational Human Stem Cell Research (October 3, 
2005), http://www.nih.gov/news/pr/oct2005/od-03.htm 
(last visited June 30, 2007). 
189 Medical News Today, US, U.K. Embryonic Stem 
Cell Banks to Announce Partnership to Promote 
Research, Create Standards (February 16 2007), http://
w w w. m e d i c a l n e w s t o d a y. c o m / m e d i c a l n e w s .
php?newsid=63078 (last visited June 30, 2007). 
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free flow of new and valuable information. 
From this perspective, the commercial goals 
of industry and the scientific goals of 
academia can be more effectively balanced. 
For instance, one could conceive using open 
models at the early development stages of 
stem cell technologies and proprietary 
schemes once the basic technology has been 
perfected. In this way, the entire scientific 
community would be able to both access the 
basic technology and then profit from 
individual improvements made to it. By the 
same token, the crucial foundational research 
would not be delayed thereby allowing 
clinical adaptations of the technologies to be 
released in a timely manner. Or, another 
possibility is a hybrid technology transfer 
scheme: maintain traditional property 
rights but incorporate certain “open” 
elements into the licenses. In other words, 
although a stem cell invention would be 
subject to a patent (for the financial benefit 
of the inventor), the inventor would allow 
unrestricted access and use of it on the 
condition that any subsequent improvements 
be made publicly available (for the academic 
benefit of the research community).
CONCLUSION
This article explored the interplay between 
proprietary and open technology management 
mechanisms and their respective effects on 
the advancement of stem cell research. 
It was seen that the conventional intellectual 
property rights scheme is currently under fire 
because of the potentially negative effect it 
may be having on technology transfer and 
thus, on scientific progress. However, due to 
the unconfirmed nature of these critiques, the 
collaborative technology transfer solutions 
put forth by some scholars to address these 
concerns could be somewhat premature 
and misdirected. 
This article posits that collaborative 
models of technology transfer should be 
considered for their remarkable ability to 
maintain or increase the pace and quality of 
scientific development in stem cell research 
rather than for their potential to fix problems 
that do not empirically exist. In light of this 
scientific field’s logistical constraints and 
its current stage of development, the open 
model appears to be a particularly suitable 
collaborative method of technology 
management for stem cell research. Moreover, 
case studies of  successful  ongoing 
collaborative projects suggest that an eventual 
introduction of open models could yield more 
positive results. In retrospect, although not 
an outright substitute for the proprietary 
protection regime, open models could be used 
in conjunction with traditional intellectual 
property rights to ensure that society will reap 
the benefits of this potent field of knowledge. 
Integrating open models in the field of 
stem cell research could also revive the 
humanitarian approach to academic sciences 
that has, of late, been weakened by commercial 
pressures. Indeed, an over reliance on the 
patent system in key medical research fields 
could result in more than foundational 
innovation being lost down the rabbit hole.
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